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ABSTRACT 
 Infertility and spontaneous abortion (SAB) affect up to one-third of couples 
planning a family.1–3 While common, there are few known risk factors. Medication 
use may play a role but the extent is unknown because, for most agents, use 
during reproduction has been understudied. The objective of this dissertation was 
to examine the associations between use of common pharmacologic agents and 
reproductive outcomes in three interrelated prospective cohort studies of 
pregnancy planners in Denmark, the United States, and Canada. 
 In study 1, we examined fecundability, the average per-cycle probability of 
conception and a measure of time-to-pregnancy (TTP), in relation to past 
contraceptive use. Exposures of interest included oral contraceptives, IUDs 
(hormonal, copper), rings, implants, patches, injectables, natural methods, and 
barrier methods. Among 9,350 female pregnancy planners, we first examined 
TTP by the last method of contraception used before pregnancy attempt. We 
then examined the association between total lifetime duration of use of hormonal 
contraceptive methods and TTP. On average, injectable users had the longest 
delay in the return of fertility (8 cycles), followed by OC, ring, implant and patch 
  vii 
(3 cycles), hormonal IUD (2 cycles), and copper IUD users (1 cycle). We did not 
find any evidence that long-term use of these methods was detrimental to 
fecundability.  
 Study 2 examined the association between male use of pain medications 
and fecundability among 1,065 couples planning pregnancy in North America. 
Medications examined include ibuprofen, acetaminophen, naproxen, and aspirin. 
We examined fecundability in relation to any use and cumulative monthly dose of 
each of these medications. Our study showed little evidence of a deleterious 
effect of male preconception use of common pain medications on fecundability. 
 In study 3, we examined use of pain medications between pregnancy 
conception and 12 gestational weeks and risk of SAB. Medications examined 
include ibuprofen, acetaminophen, naproxen, aspirin, and opioids. In the three 
cohorts of women recruited before conception, we observed 9,196 pregnancies 
and 1,597 SABs (17.4%). We found that low-dose use of ibuprofen, naproxen, or 
opioids before 12 weeks of gestation was associated with slightly increased risk 
of SAB. Overall, low-dose use of acetaminophen or aspirin did not appreciably 
increase risk of SAB. 
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1 INTRODUCTION 
Infertility and spontaneous abortion (SAB) are common reproductive 
problems with few identified risk factors. Estimates of the prevalence of current 
infertility, defined as the inability to conceive during 12 months of regular 
unprotected intercourse, vary widely. In the United States, estimates range from 
6.0%1 to 15.5%2 of women ages 15–44. Infertility can be attributed to one or both 
partners. It is thought that approximately 33% of infertility can be attributed to the 
female partner, 20% can be attributed to male partner, 39% can be attributed to 
both partners, and 8% remains unknown.3 The primary explanations for infertility 
are thought to be ovulatory disorders among females and reduced sperm motility 
among males.3,4 Known predictors of infertility include older maternal age5, and 
conditions such as pelvic inflammatory disease6 and endometriosis.7 Modifiable 
risk factors and cause of these reproductive disorders remain largely unknown.  
Spontaneous abortion (SAB), defined as the loss of pregnancy before 20 
weeks of gestation, is a common pregnancy outcome that affects approximately 
20% of clinically recognized pregnancies.8 While there is substantial research on 
SAB, there are relatively few known risk factors.9,10 The methodological 
challenges in studying SAB have led to few consistent clinical recommendations 
to reduce risk of pregnancy loss. Examination of pharmacologic agents on SAB 
risk have often been conducted in large administrative databases11–13 or post-
conception cohorts.14–16 These study designs often fail to capture SABs that 
occur before women visit healthcare providers and could result in considerable 
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bias.   
Medication use among men and women of childbearing age is common.17–
19 In 2005, the majority of reproductive-aged women in the United States used 
over the counter or prescription medications.18 Because pharmacologic agents 
are used so widely periconceptionally, even small increases in the risk of 
infertility or SAB would have a large public health impact. Information about the 
reproductive safety of medications is often limited, even for common medications 
such as pain relievers.  
Using prospectively collected data from Danish and North American 
pregnancy planners, this dissertation examined female pregravid use of 
contraceptives and fecundability (Chapter 2), male pain-reliever use and 
fecundability (Chapter 3), and early pregnancy use of pain-relievers and risk of 
spontaneous abortion (Chapter 4).  
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1.1 References 
2 PREGRAVID CONTRACEPTION USE AMONG FEMALES AND 
FECUNDABILITY 
2.1 Introduction 
 Long-acting reversible contraceptive (LARC) methods and the 
contraceptive ring have gained popularity among women wanting to avoid 
pregnancy.20 These methods include intrauterine devices (IUDs), implants, and 
injectable contraceptives.21 In Europe, 10% of women used LARC methods in 
2006.22 In the United States (U.S.), 2% of women ages 25–34 used LARC 
methods in 1995 compared with 11% in 2011–2013.23 The contraceptive ring, an 
effective alternative to oral contraceptives (OCs), has had quick uptake since its 
approval in 200124 and was used by 7% of US women in 2006–2010.20 
 These contraceptive methods often contain a progestin (OCs, implants, 
injectables, patches, rings, hormonal IUD) and estrogen (OCs, patches, rings) 
and have a variety of mechanisms of action including preventing ovulation (OCs, 
implants, injectables, patches, and rings), thinning the uterine lining to prevent 
implantation and thickening cervical mucus to prevent semen transport (OCs, 
hormonal IUD, implants, patches, rings, and injectables), and providing a barrier 
between sperm and egg (hormonal IUD and copper IUD). While the mechanisms 
of the IUDs are not fully understood, the copper IUD additionally damages sperm 
to prevent successful fertilization.25 Effects of these contraceptives may persist 
after discontinuation and leading to delayed conception. 
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Research on contraception and fertility has focused primarily on OCs. 
Studies have consistently found slight delays in return of fertility after cessation of 
OC use.26,27 Women who use OCs for long durations may have increased 
fecundability when compared with short-term users,26,28 but results have been 
inconsistent.29 Less is known about the association between ceasing use of 
alternative methods of contraception and fertility. When compared with barrier 
methods, IUDs (copper and hormonal combined) have been associated with 
slightly increased time to conception,27,30 but results are conflicting29,31 and could 
be confounded by parity. One study suggested that injectable use may be 
associated with increased time to conception.29 Most studies examining less 
common contraceptive methods have been retrospective27,30 and/or 
underpowered.29–31  
There is limited information about fertility after use of IUDs, injectables, 
rings, implants, or patches. Using prospectively collected data, this study 
examines fecundability among women who discontinued contraception in order 
to conceive. As women delay childbearing, timing of return of fertility may be an 
important factor in contraceptive choice among pregnancy planners. 
2.2 Methods 
2.2.1 Study Population 
To enhance sample size, data from three prospective cohort studies of 
pregnancy planners were pooled for this analysis: 1) In Denmark, Snart Gravid 
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(SG) (2007–2011)32 enrolled female pregnancy planners ages 18–49 years; 2) 
Snart Foraeldre (SF) (2011–2017), an extension of SG, also includes male 
partners;33  3) in the U.S. and Canada, Pregnancy Study Online (PRESTO) 
(2013–2017)34 enrolls female pregnancy planners ages 21–45 and their male 
partners. Recruitment for SF and PRESTO is ongoing. 
Participants in all studies were recruited primarily using advertisements on 
social media and health-related websites. Eligible women were in a relationship 
with a male partner, not pregnant, and not using contraception or fertility 
treatments.  
All questionnaires were administered online. At baseline, participants 
reported exposure and covariate information including self-reported 
demographics, lifestyle factors, and medical history. Follow-up questionnaires 
were administered every two months for 12 months or until reported pregnancy. 
Over 80% of participants completed at least one follow-up questionnaire.34,35 The 
Danish Data Protection Board and Boston University Medical Center institutional 
review board approved the study protocol and participants provided online 
informed consent. 
2.2.2 Assessment of Contraceptive Use 
At baseline, participants reported the contraceptive method they used last, 
before beginning their conception attempt. Categories included barrier methods 
(condoms, diaphragm, sponge, jells/foams/creams/suppositories), OCs, 
hormonal IUDs, copper IUDs, patches, injectables, rings, implants, and natural 
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methods (withdrawal, calendar methods, monitoring cervical mucus or basal 
body temperature, avoiding sex during fertile window). Recent users of hormonal 
methods were asked if they waited for a period of time after discontinuing this 
method before attempting to conceive.  
In PRESTO, women also reported the total number of hormonal 
contraceptives (e.g. OCs, rings, implants, hormone IUDs) they have ever used, 
the name of each method, and their ages at initiation and cessation of each. In 
SF and SG, a detailed history of use was only collected for OCs. For PRESTO, 
duration was calculated separately for each type of hormonal contraceptive by 
summing the years of use.  
2.2.3 Assessment of Pregnancy and Menstrual Cycles at Risk 
At baseline, participants reported their usual menstrual cycle length, their 
date of last menstrual period (LMP), and the number of cycles they had been 
trying to conceive. At each follow-up, participants reported their LMP date, 
pregnancy status primarily confirmed using home pregnancy tests (>96%), and 
information about time-varying covariates. Total cycles at risk were calculated as 
(cycles trying to conceive at study entry) + [(LMP date from most recent follow-up 
questionnaire - date of baseline questionnaire)/cycle length] + 1.  
2.2.4 Exclusions 
Participants were excluded if they did not complete at least 1 follow-up 
questionnaire, if they reported insufficient or implausible menstrual cycle 
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information, or if they had been trying to conceive for >6 cycles at study entry.  
We also excluded women if they used a contraceptive method not examined 
(e.g. reversed sterilization). The final analytic sample included 3,966 women from 
SG, 2,367 women from SF, and 3,017 women from PRESTO for a combined 
total of 9,350 women (Figure 2.1). 
2.2.5 Data Analysis 
Women contributed at-risk cycles to the analysis beginning at study entry 
until reported pregnancy, initiation of fertility treatment, withdrawal, loss-to-follow-
up, or 12 cycles, whichever occurred first. We first examined the association 
between fecundability and use of OCs, hormonal IUDs, copper IUDs, rings, 
implants, patches, injectables, and natural methods as the last method of 
contraception compared with barrier methods. Next, we compared fecundability 
after use of hormonal versus copper IUDs. We then examined fecundability for 
each method by cycle of pregnancy attempt compared with barrier methods as a 
method that presumably has no persistent effects upon cessation. Lastly, we 
examined the total duration of use of each hormonal method. Total duration was 
split into two-year categories and compared with <2 years of use. 
We used proportional probabilities models to estimate fecundability ratios 
(FRs) and 95% confidence intervals (CIs).36 The FR is a measure of the average 
per-cycle probability of conception comparing users of a specific contraceptive 
method with the reference group. The proportional probabilities model adjusts for 
cycle at risk, taking into account average declining fecundability as fertile couples 
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conceive and are removed from the denominator over time.37 We used the 
Andersen-Gill data structure to account for differences in attempt time at 
enrollment (0–6 cycles) and to reduce bias from left truncation.38,39 For example, 
if a woman entered the study with 3 cycles of attempt time and conceived during 
her 6th cycle, she would contribute cycles 4–6 to the analysis. We also used the 
weighted copy method to reduce convergence issues associated with the log 
binomial model.40 
Models were adjusted for potential confounders selected a priori based on 
the literature and a directed acyclic graph. These included cohort (SG, SF, 
PRESTO), age (<25, 25–29, 30–34, ≥35 years), education (≤12, 13–15, 16, ≥17 
years), non-Hispanic white (yes versus no), income (< versus ≥ 50,000 
USD/300,000 DKK per year), current smoking (yes versus no), BMI (<25, 25–29, 
≥30 kg/m2), baseline intercourse frequency (<1, 1–3, ≥4 times per week), doing 
something to improve chances of conception (e.g. timing intercourse during the 
fertile window, monitoring cervical mucus) (yes versus no), physician diagnosed 
endometriosis (yes versus no), physician diagnosed uterine leiomyomata (yes 
versus no), physician diagnosed  diabetes (yes versus no) and lifetime duration 
of hormonal contraceptive use (months; SG/SF: OCs only, PRESTO: all 
hormonal contraceptives) 26. Models were run with and without adjustment for 
menstrual cycle characteristics (regularity: yes versus no; length: ≤21, 22–35, 
≥36 days; and flow heaviness: yes versus no) and parity (0, ≥1 births), as these 
may be causal intermediates.41 
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Results for most recent type of contraception were examined separately 
by cohort (SG, SF, PRESTO) to examine the impact of potential biases 
stemming from minor difference in data collection or differences by country, age 
(<30 versus ≥30 years) to determine any differences in delay by baseline 
fecundity, attempt time at study entry (0–2 versus 3–6 cycles) to examine 
changes in effect with increasing attempt time, and BMI (<30 versus ≥30 kg/m2) 
as effectiveness of hormonal contraceptives may vary by BMI.42 We also 
stratified by history of infertility (i.e., 12 months of unprotected intercourse without 
conception) (yes versus no), and parity (0 versus ≥1 births) to explore residual 
confounding by indication. 
We used PROC MI to impute missing values for exposures and covariates 
to create five datasets. 2.4% of participants were missing last method of 
contraception. Duration of use for each type of hormonal contraceptive was 
imputed for between 0.2% (implants) and 17.1% of participants (OCs). We used 
PROC MIANALYZE to combine coefficient and standard error estimates.43 
2.3 Results 
OCs (42.9%), barrier methods (30.9%), and natural methods (12.9%) 
were the most commonly-used last methods of contraception. The most 
commonly-used LARC methods were IUDs, with 5.4% and 3.7% of women last 
using the hormonal and copper IUD, respectively. Compared with users of all 
other methods, IUD users were more likely to be older and parous; injectable and 
implant users were less likely to identify as non-Hispanic white and more likely to 
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have a lower household income; and patch and injectable users were more likely 
to report lower educational attainment. Injectable users were also more likely 
than users of other methods to report a history of infertility or diabetes, and patch 
and implant users were more likely to report endometriosis (Table 2.1). 9,350 
women contributed a total of 39,261 menstrual cycles and 6,215 pregnancies to 
the analysis.  
2.3.1 Last Method of Contraception 
Overall, after adjusting for potential confounders, use of OCs (FR=0.90, 
95% CI: 0.85–0.95) or injectables (FR=0.73, 95% CI: 0.46–1.14) as the last 
method of contraception was associated with decreased fecundability compared 
with barrier methods.  On average, last use of hormonal IUDs, copper IUDs, 
rings, implants, patches or natural methods was not meaningfully associated with 
fecundability compared with barrier methods. There was little difference in 
fecundability comparing the copper and hormonal IUDs. While adjustment for 
menstrual cycle characteristics did not appreciably change the results (data not 
shown), there is evidence of confounding by parity as adjustment attenuated the 
slight increase in fecundability observed when comparing the hormone and 
copper IUDs with barrier methods (Table 2.2).  
Figure 2 and Table 3 display the cycle-specific probability of conception 
and FRs, respectively, for recent users of different methods of contraception 
(Figure 2.2). Compared with barrier methods, we observed varying delays in 
return of fertility for recent users. On average, return of fertility was delayed by 8 
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cycles for injectable users, 3 cycles for users of OCs, rings, implants, and 
patches, 2 cycles for copper IUD users, and 1 cycle for hormonal IUD users 
(Table 2.3).  
 Relative to barrier method use, use of OC as the last method of 
contraception was associated with decreased fecundability among women trying 
to conceive for 0–2 cycles at study entry (FR=0.85, 95% CI: 0.80–0.91) but not 
3–6 cycles (FR=1.05, 95% CI: 0.93–1.17), consistent with a short-term delay in 
return of fertility. Results were similar when stratifying by age, BMI, parity and 
history of infertility (Table 2.4) and when analyzing the cohorts separately (Table 
2.5).  
2.3.2 Lifetime Duration of Use 
In a subgroup analysis of PRESTO participants, there was no evidence of 
decreased fecundability with longer total lifetime duration of use of OCs, rings, 
injectables, hormonal IUDs, implants, and patches (Table 2.6). 
2.4 Discussion 
In this prospective cohort of pregnancy planners, we found that users of 
OCs and some LARC methods experienced short-term delays in return of fertility 
compared with barrier method users. On average, injectable users had the 
longest delay in the return of fertility (8 cycles), followed by OC, ring, implant and 
patch (3 cycles), hormonal IUD (2 cycles), and copper IUD users (1 cycle). We 
did not find any evidence that long-term use of these methods was detrimental to 
fecundability.  
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The delay in return of fertility we observed is consistent with our previous 
study examining OC use in a subset of the SG cohort.26 Our results are also 
consistent with additional literature finding slight delays in return of fertility after 
use of OCs,27  IUDs,27,30 and implants.29 Use of OCs, rings, and patches inhibits 
ovulation25,44,45 and may suppress ovarian function immediately after 
discontinuation.46 In cycle-specific analyses we observed reduced fecundability 
among participants who recently used these methods.   
Our finding of reduced fecundability after injectable use was consistent 
with previous studies.29,47 The level of progestin in injectables inhibits ovulation 
and may result in suppressed ovarian function for much longer than 90 days, the 
recommended interval between injections.48,49 Women were likely attempting to 
conceive when the medication was still active. This would explain the reduced 
fecundability overall and the 8 cycle delay in the return of fertility. However, 
characteristics of injectable users were different than barrier method users. 
Residual confounding by unmeasured factors, such as overall health and 
reproductive health knowledge, may explain part of the observed association. 
Further, loss to follow-up was higher among injectable users than non-users. If 
use of injectables causes reduced fecundability, our results would underestimate 
the detrimental effect of injectables on fecundability. 
The mechanisms by which IUDs prevent pregnancy is not fully 
understood. Previous research on IUDs and fecundability has primarily examined 
IUDs as one group and not separately by type.27,30,31 Overall, we did not observe 
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a meaningful difference in fecundability comparing hormonal and copper IUDs. 
We did, however, observe a slightly longer delay in return of fertility among 
hormonal IUD users. This difference may result from the progestin-induced 
thinning of the uterine lining that occurs with hormonal IUD use.50  
Previous studies, including one based on the SG cohort,26 observed a 
small increase in fecundability after long-term OC use.26,28 As ovulation may 
cease during use,25 some51,52 but not all53–55 studies suggest that long-term use 
may help to maintain ovarian reserve levels. Our analysis of PRESTO 
participants showed no detrimental effect of long-term OC use on fecundability 
but does not suggest any considerable improvement. 
This study has several limitations. While the large sample allowed for 
evaluation of less common methods of contraception, there were still small 
numbers of users of injectables, rings, and implants, limiting precision of the 
results. As discussed, contraceptive choice may relate to underlying fertility and 
residual confounding may partially explain our results. While we adjusted for 
contraindications and demographic and lifestyle factors, residual confounding by 
unmeasured factors (e.g. undiagnosed reproductive disorders), is still possible. 
Further, some misclassification of the cycle of conception was likely. This 
calculation relies on reported menstrual cycle length and date of the LMP and 
accuracy may differ by last contraceptive method. For example, if women with 
irregular cycles were more likely to use OCs than barrier methods, and their 
cycle of conception was more likely to be misclassified, the results could be 
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biased in either direction. Additionally, a selection bias could occur if participation 
was related to both contraceptive use and fecundability; however, because 
women enrolled in the study before conception, selection bias arising from 
differential participation is likely to be minimal. 
Because a detailed history of use of all types of hormonal contraceptives 
was collected in PRESTO only, precision was limited for duration analyses. 
Further, reporting of contraceptive methods is likely to be less accurate for 
methods used in the distant past as compared with recently-used methods. 
Nevertheless, since contraceptive history was collected before report of 
pregnancy, any misclassification is likely non-differential. The effect of this 
misclassification would be a bias towards the null in the longest duration 
categories, and an unpredictable bias in the intermediate categories.  
 We found that use of OCs, LARC methods, and the contraceptive ring was 
associated with transient delays in the return of fertility, with injectables showing 
the longest delay (approximately 8 menstrual cycles). Our findings indicate little 
effect of long-term use of these methods. 
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Figure 2.1: Flow chart of enrollment and exclusions, Snart Gravid, Snart Foraeldre and PRESTO (N=13,466), 2007–2017  
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Table 2.1 Baseline characteristics of pregnancy planners by last method of contraception, Snart Gravid, Snart Foraeldre 
and PRESTO (N=9,350), 2007–2017  
 Barrier OC Hormonal IUD Copper IUD Ring Implant Patch Injectable Natural† 
Number of Participants N (%) 2,891 
(30.9) 
4,011 
(42.9) 
505 
(5.4) 
344 (3.7) 274 
(2.9) 
52 
 (0.6) 
32 (0.3) 33 
(0.4) 
1,208 
(12.9) 
Cohort          
          Snart Gravid 35.0 53.8 35.1 23.6 35.4 17.3 40.6 30.3 33.9 
          Snart Foraeldre 27.0 26.8 25.9 46.8 22.3 17.3 28.1   9.1 11.3 
          PRESTO 38.0 19.4 39.0 29.7 42.3 65.4 31.3 60.6 54.8 
Age (years), mean 29.2 28.3 30.4 30.3 28.8 27.1 27.8 26.9 29.9 
Partners age (years), mean 30.9 31.1 31.3 31.9 31.3 31.2 27.5 30.6 31.4 
Non-Hispanic White, % 94.6 97.8 94.7 95.6 93.4 86.6 91.6 80.1 91.5 
Annual household income <50,000 
USD/<300,000 DKK, % 
16.0 13.7 14.7 15.3 16.6 19.1 11.1 23.9 18.0 
<College degree, % 28.4 33.1 30.2 25.1 32.1 36.9 41.8 50.8 25.8 
Length of relationship  
(years), mean 
  5.9   5.1   5.8   5.5   4.7   4.7   4.8   4.4   5.6 
BMI (kg/m2), mean 24.9 24.7 25.6 24.6 25.2 28.4 21.8 27.6 25.1 
Past smoker, % 21.0 19.3 19.9 18.0 20.9 27.2 19.6 15.1 23.2 
Current smoker, %   9.0 13.9 14.0 16.5 10.5   4.4 14.1 28.4 10.8 
Parous, % 31.6 28.2 58.0 54.2 27.2 38.1 19.8 39.0 33.1 
Irregular menstrual cycle, % 22.6 23.8 20.0 15.8 20.5 24.8 22.1 30.2 19.8 
Menstrual cycle length <22 days, %   0.7   1.5   1.0   0.0   0.7   0.0   0.0   3.7   0.6 
Menstrual cycle length ≥36 days, %   9.1   9.1   6.7   5.7   8.0   9.5   5.5   1.2   7.1 
Doing something to improve chances 
of conceiving, % 
68.9 56.0 64.7 65.3 56.5 67.9 61.5 59.6 65.7 
Intercourse frequency <1 time/week, % 20.1 15.6 14.6 13.6 16.1 22.3 17.0 21.9 20.6 
Intercourse frequency ≥4 times/week, 
% 
14.8 19.3 21.2 22.3 15.8 20.5  8.4 28.4 15.5 
History of infertility, %   8.1   7.1 10.5   6.1   5.3   6.1  5.6 21.1   6.8 
Diabetes, %   1.2   1.2   1.9   1.0   2.2   0.0  2.8   5.2   1.4 
Uterine leiomyomata, %   1.7   2.5   1.7   1.6   3.4   2.2  5.5   3.7   2.2 
Endometriosis, %   2.2   2.4   3.0   2.5   4.1   6.1  5.5   3.7   2.0 
OC = Oral contraceptive, IUD = Intrauterine device, USD = U.S. dollars, DKK = Danish kroner. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or basal temperature, and avoiding sex when fertile.  
Note 1. All characteristics except for age are age-standardized to the cohort at baseline. 
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Table 2.2 Last method of contraception and fecundability among pregnancy 
planners  
Method No. of No. of Adjusted Adjusted Adjusted 
Cycles Pregs FR (95% CI)a FR (95% CI)b FR (95% CI)c 
Barrier  11,784 1,916 Reference Reference Reference 
OC 17,483 2,653 0.90 (0.85–0.95) 0.89 (0.84–0.94) 0.90 (0.85–0.95) 
Hormonal IUD   1,830    381 1.20 (1.09–1.32) 1.22 (1.11–1.35) 1.11 (1.01–1.23) 
Copper IUD   1,316    252 1.10 (0.98–1.23) 1.12 (0.99–1.26) 1.05 (0.93–1.18) 
Ring   1,199   174 0.91 (0.78–1.05) 0.93 (0.80–1.07) 0.93 (0.80–1.07) 
Implant     214     31 0.94 (0.68–1.30) 1.02 (0.74–1.41) 1.01 (0.73–1.39) 
Patch     147    22 0.91 (0.62–1.33) 0.94 (0.64–1.37) 0.98 (0.67–1.44) 
Injectable     181    17 0.67 (0.43–1.05) 0.73 (0.47–1.14) 0.73 (0.46–1.14) 
Natural†  5,107  769 0.95 (0.87–1.02) 0.97 (0.89–1.05) 0.95 (0.87–1.02) 
IUDs      
Copper IUD   1,316    252 Reference Reference Reference 
Hormonal IUD   1,830    381 1.10 (0.96–1.27) 1.12 (0.97–1.31) 1.08 (0.93–1.26) 
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Adjusted for study (SF, SG, PRESTO). 
b Models adjusted for study, age at baseline, education, race, income, BMI, intercourse 
frequency, current smoking, doing something to improve chances of conception, diabetes, 
endometriosis, uterine leiomyoma, and duration of hormonal contraception use. 
c Models adjusted for variables in b, and parity. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or basal 
body temperature, and avoiding sex when fertile. 
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Figure 2.2 Per-cycle probability of conception by last method of contraception 
 
IUD=Intrauterine device 
Note: Additional LARC methods were not displayed due to the small number of users. 
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Table 2.3 Last method of contraception and fecundability among pregnancy planners by observed cycle of attempt  
Method      
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycles 5–8 Cycles 9–12 
Barrier        
   No. of cycles 664 1,350 1,376 1,329 4,633 2,432 
   No. of pregnancies 188    407    326    199    613    183 
   Adjusted FR (95% CI)a 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   Adjusted FR (95% CI)b 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
OC       
   No. of cycles 805 1,897 2,145 2,092 6,991 3,553 
   No. of pregnancies 135    383    454    364    976    341 
   Adjusted FR (95% CI)a 0.62 (0.50–0.75) 0.66 (0.58–0.75) 0.87 (0.76–0.99) 1.11 (0.94–1.31) 1.02 (0.92–1.12) 1.16 (0.97–1.38) 
   Adjusted FR (95% CI)b 0.68 (0.44–1.05) 0.68 (0.60–0.77) 0.87 (0.77–0.99) 1.12 (0.95–1.32) 1.01 (0.92–1.12) 1.12 (0.93–1.34) 
Hormonal IUD       
   No. of cycles 120    257    262 232 669 290 
   No. of pregnancies   32      72      79   53 120   25 
   Adjusted FR (95% CI)a 0.97 (0.71–1.34) 0.94 (0.76–1.16) 1.26 (1.02–1.55) 1.51 (1.16–1.98) 1.35 (1.13–1.61) 1.12 (0.75–1.66) 
   Adjusted FR (95% CI)b 0.89 (0.65–1.21) 0.86 (0.70–1.06) 1.19 (0.97–1.46) 1.33 (1.01–1.74) 1.27 (1.06–1.52) 1.05 (0.73–1.51) 
Copper IUD       
   No. of cycles 105 183 168 140 481 239 
   No. of pregnancies   25   58   46   29   68   26 
   Adjusted FR (95% CI)a 0.79 (0.55–1.13) 1.05 (0.83–1.32) 1.13 (0.87–1.47) 1.35 (0.95–1.91) 1.05 (0.83–1.32) 1.35 (0.92–1.99) 
   Adjusted FR (95% CI)b 0.78 (0.52–1.17) 1.01 (0.80–1.27) 1.10 (0.85–1.43) 1.27 (0.90–1.80) 0.99 (0.79–1.26) 1.22 (0.82–1.82) 
Ring       
   No. of Cycles   56 117 139 129 480 278 
   No. of pregnancies   12   26   28   25   64   19 
   Adjusted FR (95% CI)a 0.76 (0.45–1.27) 0.77 (0.55–1.09) 0.81 (0.56–1.16) 1.27 (0.87–1.85) 1.02 (0.80–1.30) 0.91 (0.57–1.43) 
   Adjusted FR (95% CI)b 0.82 (0.51–1.34) 0.74 (0.52–1.05) 0.83 (0.58–1.19) 1.36 (0.93–1.98) 1.04 (0.82–1.32) 0.92 (0.60–1.40) 
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Adjusted for study (SF, SG, PRESTO). 
b Models adjusted for study, age at baseline, education, race, income, BMI, intercourse frequency, current smoking, doing something to 
improve chances of conception, diabetes, endometriosis, uterine leiomyoma, and duration of hormonal contraception use. 
c Models adjusted for variables in b, and parity. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or basal body temperature, and avoiding sex when 
fertile.  
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Table 2.3 Continued. Last method of contraception and fecundability among pregnancy planners by observed cycle of attempt 
Method      
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycles 5–8 Cycles 9–12 
Implant       
   No. of cycles 8 20 32 27 81 46 
   No. of pregnancies 3   2   6   4 13   3 
   Adjusted FR (95% CI)a 1.32 (0.54–3.25) 0.35 (0.10–1.31) 0.81 (0.39–1.67) 1.05 (0.42–2.62) 1.30 (0.79–2.15) 0.93 (0.31–2.78) 
   Adjusted FR (95% CI)b 1.34 (0.57–3.14) 0.39 (0.10–1.43) 0.87 (0.42–1.79) 1.06 (0.43–2.60) 1.52 (0.92–2.50) 0.91 (0.34–2.44) 
Patch       
   No. of Cycles 3 15 19 19 59 32 
   No. of pregnancies 0   1 3 3 11   4 
   Adjusted FR (95% CI)a -- 0.22 (0.03–1.47) 0.66 (0.23–1.86) 1.02 (0.36–2.88) 1.41 (0.82–2.41) 1.57 (0.62–3.95) 
   Adjusted FR (95% CI)b -- 0.25 (0.04–1.63) 0.72 (0.26–2.01) 1.06 (0.37–2.98) 1.51 (0.88–2.58) 1.47 (0.60–3.64) 
Injectable       
   No. of cycles 2   8 15 22 78 56 
   No. of  pregnancies 0   1   1   1   7   7 
   Adjusted FR (95% CI)a -- 0.43 (0.07–2.67) 0.29 (0.04–1.90) 0.32 (0.05–2.12) 0.71 (0.35–1.44) 1.77 (0.88–3.57) 
   Adjusted FR (95% CI)b -- 0.41 (0.07–2.53) 0.37 (0.06–2.39) 0.34 (0.05–2.29) 0.79 (0.39–1.61) 1.65 (0.76–3.58) 
Natural†       
   No. of cycles 266 598 651 622 1,946 1,024 
   No. of pregnancies   20 134 141 114    245   75 
   Adjusted FR (95% CI)a 0.83 (0.63–1.09) 0.78 (0.65–0.94) 0.90 (0.75–1.09) 1.24 (0.99–1.54) 1.00 (0.87–1.15) 1.02 (0.78–1.33) 
   Adjusted FR (95% CI)b 0.84 (0.62–1.15) 0.79 (0.66–0.94) 0.91 (0.77–1.09) 1.21 (0.97–1.51) 1.00 (0.87–1.16) 1.02 (0.80–1.30) 
       
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Adjusted for study (SF, SG, PRESTO). 
b Models adjusted for study, age at baseline, education, race, income, BMI, intercourse frequency, current smoking, doing something to 
improve chances of conception, diabetes, endometriosis, uterine leiomyoma, and duration of hormonal contraception use. 
c Models adjusted for variables in b, and parity. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or basal body temperature, and avoiding sex when 
fertile.  
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Table 2.4 Last method of contraception and fecundability among pregnancy planners stratified by age and attempt time at study 
entry 
 No. of No. of Adjusted Adjusted  No. of No. of Adjusted Adjusted 
Method Cycles Pregs FR (95% CI)a FR (95% CI)b  Cycles Pregs FR (95% CI)a FR (95% CI)b 
 Age<30  Age≥30 
Barrier   6,425 1,086 1.00 (Reference) 1.00 (Reference)  5,359    830 1.00 (Reference) 1.00 (Reference) 
OC 11,099 1,707 0.89 (0.83–0.96) 0.89 (0.83–0.96)  6,384    946 0.90 (0.83–0.98) 0.91 (0.83–0.99) 
Hormonal IUD      778    167 1.22 (1.05–1.40) 1.07 (0.92–1.23)  1,052    214 1.18 (1.04–1.35) 1.14 (1.00–1.30) 
Copper IUD      537    117 1.21 (1.03–1.43) 1.12 (0.95–1.32)     779    135 1.01 (0.86–1.19) 0.98 (0.83–1.15) 
Ring      781    112 0.87 (0.73–1.04) 0.89 (0.74–1.07)     418      62 0.96 (0.76–1.22) 0.97 (0.77–1.22) 
Implant       140       21 0.95 (0.64–1.41) 0.98 (0.66–1.44)       74        10 0.89 (0.50–1.57) 0.98 (0.55–1.72) 
Patch        94      13 0.83 (0.50–1.36) 0.90 (0.55–1.48)       53        9 1.03 (0.57–1.86) 1.07 (0.60–1.94) 
Injectable      141      12 0.58 (0.34–0.99) 0.65 (0.38–1.11)       40        5 0.98 (0.44–2.22) 0.98 (0.44–2.19) 
Natural†   2,443    400 0.97 (0.87–1.10) 0.97 (0.86–1.08)  2,664    369 0.91 (0.81–1.02) 0.93 (0.83–1.05) 
IUDs          
Copper IUD      537    117 1.00 (Reference) 1.00 (Reference)     779    135 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD      778    167 1.01 (0.82–1.24) 0.96 (0.78–1.19)  1,052    214 1.17 (0.96–1.42) 1.18 (0.96–1.46) 
 Trying 0–2 cycles at study entry  Trying 3–6 cycles at study entry 
Barrier    7,927 1,454 1.00 (Reference) 1.00 (Reference)  3,857 462 1.00 (Reference) 1.00 (Reference) 
OC 11,962 1,914 0.84 (0.79–0.90) 0.85 (0.80–0.91)  5,521 739 1.08 (0.97–1.21) 1.05 (0.93–1.17) 
Hormonal IUD   1,359    288 1.12 (1.00–1.25) 1.05 (0.94–1.17)     471   93 1.55 (1.27–1.89) 1.38 (1.13–1.69) 
Copper IUD      944    199 1.08 (0.94–1.23) 1.03 (0.90–1.17)     372   53 1.19 (0.92–1.55) 1.14 (0.87–1.48) 
Ring      769    127 0.89 (0.76–1.06) 0.92 (0.78–1.09)     430   47 0.95 (0.72–1.26) 0.94 (0.71–1.25) 
Implant      160      23 0.86 (0.59–1.26) 0.91 (0.63–1.32)       54      8 1.28 (0.68–2.43) 1.46 (0.77–2.75) 
Patch      106      14 0.73 (0.45–1.18) 0.82 (0.51–1.33)       41     8 1.71 (0.93–3.14) 1.60 (0.86–2.96) 
Injectable     106        6 0.38 (0.18–0.82) 0.45 (0.21–0.97)       75   11 1.21 (0.70–2.08) 1.22 (0.71–2.11) 
Natural†   3,673    585 0.90 (0.82–0.99) 0.90 (0.83–0.99)  1,434 184 1.11 (0.94–1.31) 1.10 (0.94–1.30) 
IUDs          
Copper IUD      944    199 1.00 (Reference) 1.00 (Reference)     372   53 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD   1,359    288 1.05 (0.89–1.23) 1.03 (0.88–1.22)     471   93 1.34 (0.98–1.83) 1.20 (0.85–1.70) 
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Model adjusted for study. 
b Models adjusted for study, age at baseline, education, race, income, BMI, intercourse frequency, current smoking, doing something to 
improve chances of conception, diabetes, endometriosis, uterine leiomyoma, duration of hormonal contraception use and parity. 
Note 1: Stratified models for age were adjusted for a continuous age. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or body temperature, and avoiding sex when fertile.  
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Table 2.4 Continued. Last method of contraception and fecundability among pregnancy planners stratified by BMI and history of 
infertility 
 No. of No. of Adjusted Adjusted  No. of No. of Adjusted Adjusted 
Method Cycles Pregs FR (95% CI) a FR (95% CI)b  Cycles Pregs FR (95% CI) a FR (95% CI)b 
 BMI <30 kg/m2  BMI≥30 kg/m2 
Barrier    9,639 1,651 1.00 (Reference) 1.00 (Reference)  2,145 265 1.00 (Reference) 1.00 (Reference) 
OC 14,930 2,361 0.90 (0.85–0.96) 0.91 (0.86–0.96)  2,553 292 0.84 (0.71–0.98) 0.82 (0.69–0.96) 
Hormonal IUD   1,408    323 1.26 (1.13–1.40) 1.14 (1.03–1.27)     422   58 1.01 (0.78–1.32) 0.97 (0.74–1.26) 
Copper IUD   1,140    220 1.07 (0.94–1.21) 1.02 (0.90–1.16)     176   32 1.31 (0.94–1.81) 1.19 (0.86–1.64) 
Ring      970    149 0.90 (0.77–1.05) 0.92 (0.79–1.07)     229   25 0.97 (0.66–1.42) 0.97 (0.66–1.42) 
Implant      126      23 1.11 (0.77–1.60) 1.17 (0.81–1.68)       88     8 0.71 (0.37–1.39) 0.69 (0.35–1.34) 
Patch      113      17 0.89 (0.58–1.37) 0.96 (0.62–1.48)       34     5 1.06 (0.47–2.37) 0.97 (0.43–2.17) 
Injectable      114      13 0.75 (0.45–1.24) 0.76 (0.46–1.26)       67     4 0.57 (0.22–1.47) 0.77 (0.30–1.99) 
Natural†   4,214    680 0.96 (0.88–1.05) 0.96 (0.89–1.05)     893   89 0.81 (0.64–1.02) 0.82 (0.64–1.03) 
IUDs          
Copper IUD   1,140    220 Reference Reference     176   32 Reference Reference 
Hormonal IUD   1,408    323 1.19 (1.02–1.38) 1.15 (0.98–1.34)     422   58 0.82 (0.54–1.23) 0.89 (0.67–1.19) 
 No History of Infertility  History of Infertility 
Barrier  10,607 1,797 1.00 (Reference) 1.00 (Reference)  1,177 119 1.00 (Reference) 1.00 (Reference) 
OC 16,344 2,504 0.88 (0.83–0.93) 0.89 (0.84–0.94)  1,139 149 1.13 (0.90–1.43) 1.06 (0.91–1.23) 
Hormonal IUD   1,605    337 1.17 (1.06–1.30) 1.06 (0.95–1.17)     225   44 1.56 (1.14–2.14)  1.18 (0.74–1.88) 
Copper IUD   1,197    236 1.09 (0.97–1.23) 1.03 (0.91–1.16)     119   16 1.20 (0.74–1.93) 1.06 (0.81–1.39) 
Ring   1,117    168 0.90 (0.78–1.05) 0.92 (0.79–1.06)       82     6 0.66 (0.30–1.46) 0.86 (0.57–1.30) 
Implant      203      28 0.87 (0.62–1.22) 0.93 (0.66–1.31)       11     3 2.39 (0.93–6.13) 1.42 (0.67–3.01) 
Patch      138      21 0.88 (0.60–1.31) 0.97 (0.66–1.42)         9     1 1.29 (0.20–8.10) 1.07 (0.43–2.64) 
Injectable      131      13 0.67 (0.40–1.12) 0.71 (0.43–1.18)       50     4 0.96 (0.37–2.46) 1.13 (0.72–1.78) 
Natural†   4,651    731 0.95 (0.88–1.03) 0.95 (0.87–1.03)      456   38 0.82 (0.57–1.18) 0.94 (0.79–1.13) 
IUDs          
Copper IUD   1,197    236 1.00 (Reference) 1.00 (Reference)     119   16 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD   1,605    337 1.08 (0.93–1.26) 1.04 (0.89–1.22)      225   44 1.23 (0.74–2.05) 1.16 (0.71–1.88) 
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Model adjusted for study. 
b Models adjusted for study, age at baseline, education, race, income, BMI, intercourse frequency, current smoking, doing something to 
improve chances of conception, diabetes, endometriosis, uterine leiomyoma, duration of hormonal contraception use and parity. 
Note 1: Stratified models for BMI were adjusted for a continuous BMI. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or body temperature, and avoiding sex when fertile.  
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Table 2.4 Continued. Last method of contraception and fecundability among pregnancy planners stratified by parity 
 No. of No. of Adjusted Adjusted  No. of No. of Adjusted Adjusted 
Method Cycles Pregs FR (95% CI)a FR (95% CI)b  Cycles Pregs FR (95% CI)a FR (95% CI)b 
 Nulliparous  Parous 
Barrier    8,355 1,219 1.00 (Reference) 1.00 (Reference)  3,429 697 1.00 (Reference) 1.00 (Reference) 
OC 13,494 1,893 0.93 (0.87–1.00) 0.91 (0.85–0.98)  3,989 760 0.89 (0.81–0.97) 0.88 (0.80–0.96) 
Hormonal IUD      796    133 1.13 (0.96–1.33) 1.12 (0.95–1.32)  1,034 248 1.07 (0.94–1.21) 1.09 (0.96–1.23) 
Copper IUD      596    100 1.05 (0.88–1.27) 1.06 (0.88–1.28)     720 152 1.00 (0.86–1.16) 1.02 (0.87–1.20) 
Ring      898    122 0.95 (0.80–1.13) 0.97 (0.82–1.15)     301   52 0.84 (0.65–1.10) 0.83 (0.64–1.07) 
Implant      170      17 0.74 (0.48–1.17) 0.82 (0.52–1.28)       44   14 1.29 (0.84–1.98) 1.27 (0.82–1.96) 
Patch      122      16 0.88 (0.56–1.38) 0.94 (0.60–1.49)       25     6 1.19 (0.61–2.34) 1.05 (0.53–2.08) 
Injectable      136      10 0.56 (0.31–1.02) 0.60 (0.33–1.08)       45     7 0.97 (0.50–1.91) 1.07 (0.55–2.09) 
Natural†   3,376    471 0.98 (0.89–1.09) 0.99 (0.91–1.06)  1,731 298 0.84 (0.74–0.96) 0.88 (0.78–1.00) 
IUDs          
Copper IUD      596    100 1.00 (Reference) 1.00 (Reference)       720 152 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD      796    133 1.11 (0.86–1.43) 1.14 (0.84–1.55)    1,034 248 1.06 (0.89–1.26) 1.07 (0.89–1.28) 
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Model adjusted for study. 
b Models adjusted for study, age at baseline, education, race, income, BMI, intercourse frequency, current smoking, doing something to 
improve chances of conception, diabetes, endometriosis, uterine leiomyoma, duration of hormonal contraception use and parity. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or body temperature, and avoiding sex when fertile.  
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Table 2.5 Last method of contraception and fecundability among pregnancy planners 
stratified by study 
 No. of No. of Unadjusted Adjusted 
Method Cycles Pregs FR (95% CI)  FR (95% CI)a 
 SG 
Barrier  4,006    718 1.00 (Reference) 1.00 (Reference) 
OC 9,401 1,450 0.86 (0.80–0.94) 0.87 (0.80–0.94) 
Hormonal IUD    645    133 1.14 (0.96–1.34) 1.05 (0.89–1.24) 
Copper IUD    326      59 1.01 (0.80–1.28) 0.90 (0.71–1.14) 
Ring    445      64 0.80 (0.63–1.02) 0.83 (0.65–1.06) 
Implant      25        6 1.29 (0.65–2.56) 1.52 (0.78–2.97) 
Patch      80        7 0.53 (0.26–1.07) 0.56 (0.28–1.13) 
Injectable      51        7 0.85 (0.43–1.69) 0.83 (0.42–1.64) 
Natural† 1,683    271 0.89 (0.78–1.02) 0.89 (0.77–1.01) 
IUDs     
Copper IUD    326      59 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD    645    133 1.11 (0.85–1.46) 1.10 (0.83–1.46) 
 SF 
Barrier  2,894 551 1.00 (Reference) 1.00 (Reference) 
OC 4,598 738 0.87 (0.79–0.96) 0.88 (0.79–0.97) 
Hormonal IUD    433 107 1.22 (1.02–1.46) 1.06 (0.88–1.27) 
Copper IUD    552 125 1.15 (0.97–1.36) 1.07 (0.90–1.27) 
Ring    237   40 0.88 (0.66–1.18) 0.93 (0.70–1.25) 
Implant      38     6 0.88 (0.43–1.82) 0.75 (0.36–1.57) 
Patch      21     8 1.63 (0.95–2.82) 1.79 (1.04–3.11) 
Injectable      22     2 0.50 (0.14–1.87) 0.53 (0.14–2.00) 
Natural†    499   99 1.00 (0.81–1.23) 0.95 (0.78–1.16) 
IUDs     
Copper IUD    433 107 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD    552 125 1.05 (0.84–1.32) 0.98 (0.78–1.23) 
 PRESTO 
Barrier  4,884 647 1.00 (Reference) 1.00 (Reference) 
OC 3,484 465 0.97 (0.87–1.08) 0.95 (0.85–1.06) 
Hormonal IUD    752 141 1.25 (1.07–1.47) 1.19 (1.01–1.40) 
Copper IUD    438   68 1.07 (0.85–1.34) 1.05 (0.84–1.32) 
Ring    517   70 1.05 (0.84–1.32) 1.04 (0.83–1.30) 
Implant    151   19 0.90 (0.59–1.37) 1.04 (0.68–1.59) 
Patch      46     7 1.02 (0.52–2.00) 1.24 (0.64–2.42) 
Injectable    108     8 0.63 (0.32–1.22) 0.72 (0.37–1.39) 
Natural† 2,925 399 0.97 (0.87–1.09) 0.99 (0.88–1.11) 
IUDs     
Copper IUD    438   68 1.00 (Reference) 1.00 (Reference) 
Hormonal IUD    752 141 1.17 (0.90–1.51) 1.06 (0.86–1.31) 
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Models adjusted for age at baseline, education, race, income, BMI, intercourse frequency, 
current smoking, doing something to improve chances of conception, diabetes, endometriosis, 
uterine leiomyoma, duration of hormonal contraception use and parity. 
† Natural methods include withdrawal, calendar methods, monitoring cervical mucus or basal 
body temperature, and avoiding sex when fertile.  
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Table 2.6 Duration of use of hormonal contraceptives when pregnancy attempt began and 
fecundability, PRESTO (N=3,033), 2013–2017 
Method 
No. of No. of Unadjusted Adjusted 
Cycles Pregs FR (95% CI) FR (95% CI)a 
OC, years     
<2 1,850 236 1.00 (Reference) 1.00 (Reference) 
2–3 1,881 270 1.09 (0.92–1.29) 1.10 (0.93–1.30) 
4–5 1,814 267 1.13 (0.94–1.34) 1.09 (0.90–1.30) 
6–7 1,607 230 1.08 (0.91–1.28) 1.09 (0.92–1.29) 
8–9 1,364 204 1.14 (0.96–1.36) 1.09 (0.92–1.31) 
10–11 1,308 180 1.04 (0.87–1.24) 1.02 (0.85–1.22) 
≥12 1,793 260 1.09 (0.92–1.29) 1.14 (0.95–1.35) 
Hormonal IUD, years     
<2    449   75 1.00 (Reference) 1.00 (Reference) 
2–3    579  104 1.00 (0.76–1.31) 0.92 (0.69–1.22) 
4–5    400   69 1.06 (0.79–1.42) 1.02 (0.75–1.41) 
≥6    173   27 0.88 (0.57–1.35) 0.86 (0.56–1.33) 
Ring, years     
<2 1,505 215 1.00 (Reference) 1.00 (Reference) 
2–3    600   92 1.08 (0.86–1.37) 1.16 (0.91–1.48) 
4–5    322   46 0.99 (0.73–1.34) 0.99 (0.73–1.35) 
6–7    195   35 1.21 (0.88–1.66) 1.25 (0.90–1.73) 
≥8    121   16 0.92 (0.57–1.46) 1.04 (0.64–1.67) 
Injectable, years     
<2    967 127 1.00 (Reference) 1.00 (Reference) 
2–3    414   48 0.96 (0.69–1.33) 0.92 (0.69–1.23) 
4–5    237   11 0.43 (0.24–0.78) 0.53 (0.21–1.34) 
6–7    103   13 0.89 (0.50–1.58) 0.87 (0.53–1.42) 
≥8      96   10 0.84 (0.47–1.50) 0.82 (0.45–1.50) 
Patch, years     
<2 1,060 151 1.00 (Reference) 1.00 (Reference) 
2–3    262   33 0.84 (0.58–1.22) 0.84 (0.58–1.21) 
4–5    122   16 0.94 (0.59–1.52) 0.79 (0.48–1.28) 
≥6      80     9 0.76 (0.39–1.48) 0.73 (0.36–1.46) 
Implant, years     
<2    169   23 1.00 (Reference) 1.00 (Reference) 
≥2    237   29 0.92 (0.54–1.56) 1.03 (0.74–1.43) 
     
FR=fecundability ratio, OC=Oral contraceptive, IUD=Intrauterine device 
a Models adjusted for age at baseline, education, race, income, BMI, intercourse frequency, 
current smoking, doing something to improve chances of conception, diabetes, endometriosis, 
uterine leiomyoma and parity. 
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3 MALE USE OF PAIN MEDICATION AND TIME-TO-PREGNANCY 
3.1 Introduction 
 Pain-relievers are the most commonly-used medication among 
reproductive-aged men in North America. In 2002, more than 20% of U.S. men 
ages 18–44 years used over-the-counter analgesics during the past week.1 
There is evidence that use increases with age, even as men transition from their 
20s to 30s.2 Use is more common among physically active men, including 
athletes3 and blue collar workers.4  
Analgesics generally reduce pain by inhibiting cyclooxygenase (COX)-1 
and -2 enzymes that synthesize prostaglandins.5,6 Prostaglandins are found 
throughout the body and have a variety of actions, including helping to maintain 
homeostasis7,8 and causing pain and inflammation.7 While their role in male 
reproduction is not fully understood, prostaglandins are a component of semen 
and stimulate smooth muscle9 facilitating erection.10,11 Low prostaglandin levels 
have been associated with reduced sperm quality,12 motility and penetration 
capacity,13 and fertility.14 Elevated COX-2 levels may also be detrimental as they 
have been associated with abnormal spermatogenesis.15,16 
Ibuprofen, aspirin, and naproxen—all non-steroidal anti-inflammatory 
drugs (NSAIDs)—have varied effects on COX-2 inhibition and prostaglandin 
synthesis,17–19 with potentially different effects on reproduction. Acetaminophen, 
the most commonly used non-NSAID pain-reliever,20 is highly effective for pain 
relief but has limited effectiveness for inflammation.21 The effect of 
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acetaminophen on prostaglandin synthesis may vary by dose, with low doses 
increasing synthesis and high doses reducing synthesis.19,22–24 
There are limited data on the influence of pain medication use on male 
fertility. Ibuprofen exposure has been linked to decreased testosterone levels in 
male mice25 and rats,26 and exposure to aspirin or naproxen have been 
associated with reduced prostaglandin levels in male rats.27,28 Exposure to 
aspirin, however, has also been associated with improved reproductive 
parameters including better semen quality in animal studies.29–32 High doses of 
acetaminophen have been associated with abnormal testicular function33 and 
decreased fertility in rodents.34,35 In vitro studies of human testes obtained from 
prostate cancer patients showed that exposure to acetaminophen or aspirin was 
associated with decreased testosterone and prostaglandin levels36 Smarr et al. 
found that men with urinary acetaminophen concentrations greater than 73.5 
ng/ml had a 35% reduction in fecundability compared with men having 
concentrations less than 5.44 ng/ml (fecundability odds ratio=0.65, 95% 0.45–
0.94).37 However, the authors did not control for indication for acetaminophen 
use. 
Although pain medications are widely used, their effects on male 
fecundability have received limited epidemiologic study. In a prospective 
preconception cohort of North American pregnancy planners, we examined time-
to-pregnancy (TTP) after male preconception use of acetaminophen, aspirin, 
ibuprofen, and naproxen. 
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3.2 Methods 
3.2.1 Study population  
We analyzed data from Pregnancy Study Online (PRESTO)38 (2013–
2017), an ongoing prospective cohort study of pregnancy planners in the United 
States (U.S.) and Canada. PRESTO enrolls female pregnancy planners ages 
21–45 years and a sample of their male partners ages ≥21 years.  
Female participants are recruited primarily using advertisements on social 
media. Eligible women are in a stable relationship with a male partner, not 
pregnant, and not using contraception or fertility treatments. Female participants 
completed a baseline questionnaire and follow-up questionnaires every two 
months for 12 months or until reported pregnancy, whichever came first. Over 
80% of female participants completed at least one follow-up questionnaire.38 
Enrolled women are asked to invite their male partner to complete a one-time 
baseline questionnaire with information on sociodemographics, lifestyle factors, 
medication use, and medical history. All questionnaires were completed online. 
In the present report, we analyzed data from eligible males who enrolled between 
June 2013 and July 2017. The Boston University Medical Center institutional 
review board approved the study protocol and participants provided online 
informed consent. 
3.2.2 Assessment of pain medication use 
 At baseline, men were asked if they used pain medication during the 
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previous 4 weeks. They were able to indicate the names of up to three 
medications using auto-complete text recognition software,39 they recorded the 
names of up to three pain medications, as well as the total number of pills used 
of each type during the past month, and the reason for use. Medications were 
grouped by active ingredient. Categories included acetaminophen, aspirin, 
ibuprofen and naproxen. Men who reported ≥1 pill in the 4 weeks before baseline 
were considered users. These groupings were not mutually exclusive; men who 
took more than one type of pain medication (e.g. ibuprofen and acetaminophen) 
or took a medication that contained more than one active ingredient (e.g. 
“Excedrin Migraine”) were classified as exposed to each of the medications 
reported. Cumulative monthly dose was calculated as the number of pills used 
during the past 4 weeks multiplied by the dose of the active ingredient(s) in each 
pill and then summed for each active ingredient. The most commonly purchased 
dose was used for medication sold in varying strengths. 
3.2.3 Assessment of pregnancy and menstrual cycles at risk 
At baseline, females reported their menstrual cycle length, date of their 
last menstrual period (LMP), and the number of cycles they had been attempting 
conception. At each follow-up, females reported their LMP date and pregnancy 
status. Over 96% of participants reported using home pregnancy tests to confirm 
pregnancy. Total cycles at risk were calculated as: (cycles trying to conceive at 
study entry) + [(LMP date from most recent follow-up questionnaire - date of 
baseline questionnaire)/cycle length] + 1.  
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3.2.4 Assessment of covariates 
On the male baseline questionnaire, participants reported data on 
sociodemographic, medical history, lifestyle factors, and indications for pain 
medication use. BMI was calculated as kg/m2, physical activity was calculated as 
metabolic equivalent of task (MET) hours/week and stress was assessed by the 
perceived stress scale (PSS-10).40 Household income, female age and 
education, intercourse frequency, and doing something to improve chances of 
conception (e.g., timing intercourse during the fertile window, monitoring cervical 
mucus) were reported by the female partner on the female baseline 
questionnaire.  
3.2.5 Exclusions 
 5,020 women completed the PRESTO baseline questionnaire. Of these 
women, we excluded 161 women with implausible menstrual cycle information 
and 881 women who had been trying to conceive for more than 6 cycles at study 
entry. Of the 3,978 remaining women, 2,186 invited their male partners to 
participate; 1,072 men enrolled. We excluded 7 men who used an NSAID other 
than those examined (i.e. celecoxib, diclofenac, meloxicam). 1,065 men were 
included in this analysis. 
3.2.6 Data analysis 
 Couples contributed cycles to the analysis beginning at study entry until 
reported pregnancy (63.7%), initiation of fertility treatment (8.3%), withdrawal 
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(0.6%), loss-to-follow-up (13.7%), or 12 cycles (13.8%). We used proportional 
probabilities regression models to estimate fecundability ratios (FRs) and 95% 
confidence intervals (CIs).41 The FR is a measure of the average per-cycle 
probability of conception comparing users of a specific pain medication with non-
users of that medication. The model adjusts for each cycle at risk to account for 
the decline in average fecundability over time when more fertile couples conceive 
sooner and are removed from the denominator.42 We used the Andersen-Gill 
data structure43 to account for left truncation bias that may result from women 
entering the study after ≥1 cycles of pregnancy attempt.44,45 For example, 
couples that entered the study with 1 cycle of attempt time and conceived during 
the 5th cycle contribute cycles 2 through 5 to the analysis. We used the “weighted 
copy method” to facilitate convergence of the log binomial model.46 
Due to the low number of participants exposed to some medications, 
models were adjusted for potential confounders selected using a hybrid approach 
to avoid overfitting. Covariates identified a priori were included one at a time in 
the unadjusted model; those that caused a ≥5% change in any medication-
specific point estimate were retained in the final models. Covariates evaluated 
included age (<25, 25–29, 30–34, ≥35 years), education (≤12, 13–15, 16, ≥17 
years), non-Hispanic white (yes versus no), income (< versus ≥ 50,000 USD per 
year), BMI (<25, 25–29, ≥30 kg/m2), use of performance enhancing supplements 
(yes versus no), vigorous physical activity (MET hours/week), occupational 
exposure to high temperatures or toxic chemicals (yes versus no), work hours 
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(<45 versus ≥45 hours/week), sleep hours (<7 versus ≥7 hours/night), alcohol 
use (drinks/week), sugar-sweetened beverage intake (drinks/week), multivitamin 
use (yes versus no), smoking (current, past, never), physician-diagnosed anxiety 
(yes versus no), physician-diagnosed depression (yes versus no), PSS-10 score 
(range 0–40), physician-diagnosed migraine headaches (yes versus no), 
physician-diagnosed hypertension (yes versus no), fever during the past 3 
months (yes versus no), past month antibiotic use (yes versus no), past month 
opioid use (yes versus no), frequency of primary care provider (PCP) visits (<3 
versus ≥3 visits per year), intercourse frequency (<1, 1–3, ≥4 times per week), 
and doing something to improve chances of conception (yes versus no). Female 
covariates examined included age (<25, 25–29, 30–34, ≥35 years), and 
education (≤12, 13–15, 16, ≥17 years). Categorical variables were included as a 
set of indicator variables (e.g. 3 variables for age). Retained covariates included 
male age, BMI, household income, intake of sugar-sweetened beverages and 
alcohol, migraine headaches, fever, and doing something to improve chances of 
conception. We adjusted for indications for medication use including headache 
(yes versus no), muscular pain (yes versus no), illness (yes versus no), 
toothache (yes versus no), insomnia (yes versus no), surgery (yes versus no), 
and cardiovascular health (yes versus no), when applicable. 
To examine potential confounding and explore effect measure 
modification by selected covariates, we conducted stratified and subgroup 
analyses. We stratified by male age (<30 versus ≥30), attempt time at study entry 
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(0–2 versus 3–6 menstrual cycles), and male BMI (<30 versus ≥30 kg/m2). We 
also conducted analyses restricted to medication users who reported common 
indications for use (headache, muscular pain, illness). Additionally, we conducted 
an analysis restricted to the first observed menstrual cycle, which was the time 
period when exposure was assessed, to examine outcomes most proximate to 
exposure. We also conducted an analysis restricted to men who did not have a 
fever during the 3 months before baseline (N=908, 85.3%), as fever is a common 
indication for pain-reliever use and fever can adversely affect spermatogenesis.47 
Next, to compare use of each medication with non-use of any pain medication, 
we restricted the analysis to users of only one type of medication and all non-
users. Lastly, we restricted analyses to users of only one type of medication and 
compared users of acetaminophen, aspirin, or naproxen to users of the most 
commonly-used medication, ibuprofen, to indirectly control for confounding by 
indication as these medications are often used for the same conditions. 
Between 0.3% (naproxen) and 1.2% (acetaminophen) of participants were 
missing data on pain-reliever dose. Pregnancy status was missing for 4.7% of 
couples. Missing covariate data ranged from 0% (13 variables including age) to 
8.7% (household income), with the exception of PSS score, fever, and indication 
for use which were missing for 50.2%, 52.1%, and 69.9% of participants, 
respectively. These items were added to the questionnaire 2–3 years after the 
study began and thus were “missing at random”.48 We used PROC MI to impute 
missing data on exposure, covariates, and pregnancy status, and used PROC 
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MIANALYZE to combine coefficient and standard error estimates from five 
imputed datasets.49  
3.3 Results 
 At baseline, more than half (51.8%) of the 1,065 males reported using a 
pain medication during the previous month. The most commonly used analgesics 
were ibuprofen (36.7%) and acetaminophen (16.8%). Fewer men used naproxen 
(5.6%) and aspirin (4.4%). Among users, the median total monthly dose of each 
medication was 1,600 mg (interquartile range (IQR): 800–2,400 mg) of ibuprofen, 
1,300 mg (IQR: 650–2,600 mg) of acetaminophen, 1,320 mg (IQR: 440–2,200 
mg) of naproxen, and 1,000 mg (IQR: 650–1,950 mg) of aspirin. The most 
common indications for use were headache (80.0%) and muscular pain (37.8%). 
Ibuprofen (40.3%) and naproxen (53.8%) users were more likely to report use for 
muscular pain, acetaminophen users were more likely report use for an illness 
(9.1%), and aspirin users were more likely to report use for headache (93.3%) or 
cardiovascular health (8.3%) when compared with users of the other 
medications. 
 Compared with non-users of any pain medication, users were more likely 
to be non-Hispanic white and past smokers of cigarettes, and to report medical 
conditions including anxiety, depression, migraines, and hypertension. They were 
also more likely to report a fever within the 3 month-period before baseline and to 
have a history of infertility. When compared with all other groups, ibuprofen use 
was positively associated with educational attainment; naproxen use was 
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positively associated with occupational exposure to high temperatures or toxic 
chemicals, income, and lower educational attainment (Table 3.1). 
 A total of 1,065 couples contributed 5,096 cycles and 678 pregnancies to 
the analysis. Compared with unadjusted analyses, results were attenuated after 
adjusting for potential confounders, including indication for medication use (Table 
2). Adjusted FRs were 1.23 for naproxen use (95% CI: 0.80–1.90), 1.15 for 
aspirin use (95% CI: 0.80–1.65), 0.93 for acetaminophen use (95% CI: 0.75–
1.15) and 0.97 for ibuprofen use (95% CI: 0.81–1.17) when compared with non-
users of each respective medication (Table 3.2). There was little evidence of an 
association between cumulative monthly dose and fecundability (Table 3.3). 
Reduced fecundability was observed among obese (FR=0.79, 95% CI: 
0.47–1.32) and younger (FR=0.68, 95% CI: 0.40–1.16) ibuprofen users 
compared with non-users, but these results were imprecise. Results for the 
examined medications were generally consistent across strata of pregnancy 
attempt time at study entry (<3 cycles vs. 3–6 cycles) (Table 3.4), and common 
indications for medication use (headache, muscular pain, or illness) (Table 3.5). 
We conducted several sensitivity analyses. When we restricted to the first 
observed menstrual cycle, results were consistent with the overall results (data 
not shown). Among men without a fever during the past 3 months, for whom 
confounding by recent illness was less likely, results were consistent with our 
overall findings (results not shown). Finally, when we assessed use of single 
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medications relative to use of ibuprofen only (reference group), fecundability was 
slightly higher among users of naproxen only and aspirin only (Table 3.6).  
3.4 Discussion  
 In this large prospective cohort of North American couples planning 
pregnancy, use of common pain medications at low cumulative doses over a 4-
week period did not have a deleterious effect on male fecundability. While use of 
naproxen or aspirin was associated with slightly increased fecundability, numbers 
of users were small and results were attenuated after adjusting for 
demographics, lifestyle factors, and indications for medication use. Our results 
were consistent among couples with shorter pregnancy attempt times at 
enrollment (≤2 menstrual cycles), among users of a single pain medication 
compared with ibuprofen, and when analyses were restricted to the first observed 
menstrual cycle. 
 Our finding of no meaningful reduction in fecundability among male 
acetaminophen users disagrees with the 35% decrease reported by Smarr et al. 
among men with urinary acetaminophen concentrations >73.5 ng/ml compared 
with <5.44 ng/ml 37. The strong inverse association found may be explained by 
unmeasured confounding by indication for use, particularly fever and infections, 
which are strong potential confounders.50 While urinary measurement of 
acetaminophen is presumably more accurate than self-reported medication use, 
capturing both medical and environmental exposures,50,51 a single spot urine 
sample measures only past-day exposure,52 a time interval that and may not be 
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etiologically relevant to conception.  
There is no previous study examining male use of naproxen, ibuprofen, or 
aspirin and fecundability. NSAIDs block COX-1 and -2 enzymes, which help form 
prostaglandins.7 The role of COX-1 and -2 enzymes and the resulting 
prostaglandins in reproduction is not fully understood.  
Our data provided no indication that male aspirin use deleteriously 
affected fertility. Aspirin’s antiplatelet activity makes it different from other 
NSAIDs.53,54 While results have been inconsistent,55–57 some animal studies 
indicate that aspirin use may improve male reproductive parameters.29–32  
 A primary limitation of the study was low precision for naproxen and 
aspirin effects, stemming from small numbers of users, and the narrow range of 
doses. Additionally, information about medication use was obtained only at 
baseline. For some couples, this assessment occurred months before they 
reached a study endpoint. It is likely that exposure changed over time. To 
address this problem, we conducted a sensitivity analysis restricted to the first 
observed menstrual cycle. Results from this analysis were consistent with the 
main analysis. Further, because we measured total number of pills over the 4 
week period, but lacked information about the timing of use and dosage patterns 
(e.g. chronic low dose, infrequent high dose), some misclassification of relevant 
exposure was inevitable. In addition, participants may have incorrectly recalled 
the name and dose of the medications used. All these sources of error were 
likely non-differential, as report of medication use occurred before the outcome 
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was known. Such non-differential misclassification would bias our effect 
estimates toward the null. Outcome misclassification, though less of a problem in 
this study, was also possible. Calculation of time-to-pregnancy relies on the 
female participant’s report of LMP date and menstrual cycle length, which may 
be reported with error. Such misclassification is expected to be non-differential 
with respect to studied exposure because any errors in the female partner’s 
reporting of LMP and menstrual cycle length are unlikely to be related to their 
male partners’ medication use. 
 Indication for use was missing for a large percentage of users because 
questionnaire items about reasons for use were added after the study began. We 
used multiple imputation to deal with missing data and thus inferred indication 
when missing from other questionnaire items. Results were attenuated after 
adjusting for our imperfect measure of indication for use; we expect that our 
results would be attenuated further had we measured indication with less error. 
To reduce residual confounding by indication, we conducted an analysis 
restricted to men who did not have a fever during the past 3 months, since fever 
is associated with pain medication use and reduced semen quality. This analysis 
showed results similar to the main analysis. Further, results were similar when 
we compared use of each medication with ibuprofen use, the most commonly 
used pain medication. Such an analysis indirectly controls for indication for use 
because over-the-counter (OTC) pain-relievers have broadly similar indications.  
As with many prospective cohort studies, we studied volunteers, recruiting 
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females and asking them to invite their male partners to participate. About 55% 
of men were invited by their female partners to participate, and of those invited, 
only 49% of males enrolled. Because the probability of conception was similar 
when comparing male and female pairs with female who participated alone, 
selection bias by participation is likely small. Selection bias by loss to follow-up is 
also unlikely to be a serious problem because medication users (90.4%) and 
non-users (88.9%) had similar proportions completing follow-up. 
 Given currently available evidence from the literature and from our 
findings, male preconception use of common OTC pain medications at low 
cumulative doses does not appear to have deleterious effects on fecundity. 
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Table 3.1 Baseline characteristics of male pregnancy planners by pain medication use, PRESTO (N=1,065), 2013–2017  
 Pain Medication Use  Type of Medication Use 
 No Yes  Ibuprofen Acetaminophen Naproxen Aspirin 
Number of Participants N (%) 513 (48.2) 552 (51.8)  391 (36.7) 179 (16.8) 60 (5.6) 47 (4.4) 
Age (years), mean 31.2 32.1  32.2 31.7 31.7 32.2 
Partners age (years), mean 29.8 30.0  30.0 30.2 30.0 30.2 
Non-Hispanic White, % 84.5 89.1  89.0 90.8 92.3 91.2 
Annual household income <$50,000 16.3 16.2  15.2 20.1   9.6 16.8 
Annual household income >$150,000 20.1 20.6  22.0 16.7 22.0 20.3 
<College degree, % 29.0 26.4  26.4 29.6 33.7 29.4 
Partner <College degree, % 15.1 15.9  15.0 16.2 14.3 16.5 
Work >45 hrs/wk, % 28.3 34.8  32.9 34.8 39.4 37.8 
Occupational exposure to high temperatures or 
toxic chemicals, % 24.2 26.0 
 25.9 28.9 32.4 25.2 
BMI (kg/m2), mean 27.4 27.9  27.7 28.1 28.7 28.4 
Sleep <7 hrs/wk, % 31.6 34.8  32.5 38.7 35.5 40.6 
Vigorous physical activity (MET-hrs/wk), mean 19.3 17.4  18.6 15.1 17.3 17.6 
Multivitamin supplement use, % 31.3 39.2  40.3 35.7 51.2 34.0 
Performance enhancing supplement use, % 10.8   9.0  10.8   7.6   6.7 13.1 
Alcohol (drinks/wk), mean   5.9   6.5    7.1   6.1   5.1   6.7 
Sugar sweetened beverages (drinks/wk), mean   4.2   4.2    3.8   5.2   3.7   4.9 
Past smoker, % 17.6 24.2  24.4 27.4 28.3 23.6 
Current smoker, %   5.5   5.0    5.0   6.1   6.1   4.5 
Doing something to improve chances of 
conceiving, % 75.6 77.1 
 77.3 76.2 81.8 76.0 
Intercourse frequency <1 time/week, % 21.2 18.5  18.5 18.1 23.7 10.7 
Intercourse frequency ≥4 times/week, % 15.4 15.5  16.2 17.0 14.7 14.2 
History of infertility, %   6.3   9.2    9.1 10.0   3.7   8.6 
Perceived Stress Scale Score, mean 14.0 15.2  14.8 16.4 17.4 15.4 
Diagnosis of anxiety, %   5.9   9.9  10.2 12.9 26.8 11.1 
Diagnosis of depression, %   8.0 12.6  11.2 16.7 17.1 19.0 
Migraine headaches, %   3.5   7.3    7.1   9.0 10.9   4.0 
Hypertension, %   6.9   8.5    8.0   9.0 12.7   8.8 
        
All characteristics except for age are age-standardized to the cohort at baseline. 
Note: Pain medication use was assessed during the 4 weeks before baseline.  
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Table 3.1 Continued. Baseline characteristics of male pregnancy planners by pain medication use, PRESTO (N=1,065), 2013–
2017  
 Pain Medication Use  Type of Medication Use 
 No Yes  Ibuprofen Acetaminophen Naproxen Aspirin 
Hypertension, %   6.9   8.5    8.0   9.0 12.7   8.8 
Fever, past 3 months, % 11.2 18.2  17.7 21.6 17.0 31.5 
Antibiotic use, %   3.1   5.0    4.1   7.2   3.0   0.0 
>3 PCP visits/year, %   5.0   7.9    7.8   9.5 14.9   5.6 
Indication        
     Headache, % -- 80.0  78.6 78.7 61.3 93.3 
     Muscular pain, % -- 37.8  40.3 38.8 53.8 30.9 
     Illness, % --   6.8    6.9   9.1 3.0 8.5 
     Toothache, % --   4.4    4.1   6.7 0.0 6.6 
     Insomnia, % --   3.8    2.6   5.6 0.0 4.3 
     Surgery, % --   3.1    2.3   4.6 1.4 4.5 
     Cardiovascular, % --   1.9    1.4   0.5 0.0 8.3 
        
 
All characteristics except for age are age-standardized to the cohort at baseline. 
Note: Pain medication use was assessed during the 4 weeks before baseline. 
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Table 3.2 Baseline pain medication use and fecundability 
Medication 
No. of No. of Unadjusted Adjusted 
Cycles Pregs FR (95% CI) FR (95% CI)a 
     
Any pain medication     
     Non-use 2,111 322 1.00 (Reference) 1.00 (Reference) 
     Any use 2,307 356 1.04 (0.91–1.19) 1.07 (0.93–1.23) 
Ibuprofenb      
     Non-use 2,773 431 1.00 (Reference) 1.00 (Reference) 
     Any use 1,645 247 0.98 (0.85–1.13) 0.97 (0.81–1.17) 
Acetaminophenb     
     Non-use 3,631 569 1.00 (Reference) 1.00 (Reference) 
     Any use    787 109 0.91 (0.75–1.09) 0.93 (0.75–1.15) 
Naproxenb     
     Non-use 4,209 636 1.00 (Reference) 1.00 (Reference) 
     Any use    209   42 1.36 (1.03–1.80) 1.23 (0.80–1.90) 
Aspirinb     
     Non-use 4,226 645 1.00 (Reference) 1.00 (Reference) 
     Any use    191   33 1.29 (0.93–1.78) 1.15 (0.80–1.65) 
     
FR=fecundability ratio  
a Models were adjusted for male age, BMI, household income, sugar sweetened beverage 
intake, alcohol intake, migraine headache, fever, and doing something to improve chances of 
conception.  
b Adjusted for all variables in footnote “a” and mutually adjusted for the other types of pain 
medications and reported indications for use. 
Note: Pain medication use was assessed during the 4 weeks before baseline.  
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Table 3.3 Baseline cumulative monthly dose of pain medication exposure and 
fecundability 
Medication 
No. of No. of Unadjusted Adjusted 
Cycles Pregs FR (95% CI) FR (95% CI)a 
     
Non-use 2,111 322 1.00 (Reference) 1.00 (Reference) 
Any use     
       Low exposure 1,357 226 1.12 (0.96–1.30) 1.13 (0.97–1.32) 
       Moderate exposure    950 130 0.93 (0.77–1.12) 0.98 (0.81–1.19) 
Ibuprofen (mg) b     
     Non-use 2,773 431 1.00 (Reference) 1.00 (Reference) 
     <2,000   983 161 1.05 (0.89–1.24) 1.01 (0.83–1.23) 
     ≥2,000   662   86 0.87 (0.70–1.08) 0.91 (0.70–1.18) 
 Acetaminophen (mg) b     
     Non-use 3,631 569 1.00 (Reference) 1.00 (Reference) 
     <2,000   515   73 0.92 (0.74–1.16) 0.92 (0.73–1.17) 
     ≥2,000   272   36 0.87 (0.64–1.20) 0.95 (0.71–1.26) 
Naproxen (mg) b     
     Non-use  4,209 636 1.00 (Reference) 1.00 (Reference) 
    <1,500   139   29 1.43 (1.03–2.01) 1.26 (0.80–1.98) 
     ≥1,500     70   13 1.23 (0.76–1.99) 1.19 (0.70–2.02) 
Aspirin (mg) b     
     Non-use 4,226 645 1.00 (Reference) 1.00 (Reference) 
     <1,500   131   21 1.21 (0.80–1.83) 1.09 (0.76–1.58) 
     ≥1,500     61   12 1.44 (0.88–2.36) 1.29 (0.70–2.36) 
     
FR=fecundability ratio 
a Models were adjusted for male age, BMI, household income, sugar sweetened beverage 
intake, alcohol intake, migraine headache, fever, and doing something to improve chances of 
conception.  
b Adjusted for all variables in footnote “a” and mutually adjusted for the other types of pain 
medications and reported indications for use. 
Note: Pain medication use was assessed as total dose during the 4 weeks before baseline. 
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Table 3.4 Baseline pain medication use and fecundability stratified by age and attempt time at study entry 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Cycles Pregs FR (95% CI) FR (95% CI)a  Cycles Pregs FR (95% CI) FR (95% CI)a 
 Age<30  Age≥30  
Any pain medication          
     Non-use    854 130 1.00 (Reference) 1.00 (Reference)  1,257 192 1.00 (Reference) 1.00 (Reference) 
     Any use    751 114 1.10 (0.88–1.39) 1.13 (0.89–1.44)  1,556 242 1.02 (0.86–1.21) 1.06 (0.89–1.26) 
Ibuprofenb           
     Non-use 1,107 175 1.00 (Reference) 1.00 (Reference)  1,666 256 1.00 (Reference) 1.00 (Reference) 
     Any use    498   69 0.94 (0.73–1.21) 0.68 (0.40–1.16)  1,147 178 1.01 (0.84–1.20) 1.10 (0.82–1.49) 
Acetaminophenb          
     Non-use 1,298 204 1.00 (Reference) 1.00 (Reference)  2,333 365 1.00 (Reference) 1.00 (Reference) 
     Any use    307   40 0.91 (0.66–1.24)   0.73 (0.43–1.25)     480   69 0.91 (0.72–1.16) 0.99 (0.76–1.23) 
Naproxenb          
     Non-use 1,541 230 1.00 (Reference) 1.00 (Reference)  2,668 406 1.00 (Reference) 1.00 (Reference) 
     Any use      64   14 1.51 (0.95–2.40) 1.21 (0.73–2.01)     145   28 1.31 (0.93–1.86) 1.28 (0.77–2.15) 
Aspirinb          
     Non-use 1,526 232 1.00 (Reference) 1.00 (Reference)  2,700 413 1.00 (Reference) 1.00 (Reference) 
     Any use      79   12 1.25 (0.74–2.12) 1.03 (0.57–1.85)     113   21 1.34 (0.89–2.02) 1.20 (0.75–1.90) 
 Trying 0–2 cycles at study entry  Trying 3–6 cycles at study entry  
Any pain medication          
     Non-use 1,449 233 1.00 (Reference) 1.00 (Reference)     662   89 1.00 (Reference) 1.00 (Reference) 
     Any use 1,627 269 1.07 (0.92–1.26) 1.13 (0.97–1.33)     680   87 0.97 (0.73–1.28) 0.90 (0.66–1.21) 
Ibuprofenb           
     Non-use 1,900 316 1.00 (Reference) 1.00 (Reference)     873   115 1.00 (Reference) 1.00 (Reference) 
     Any use 1,176 186 0.97 (0.82–1.14) 0.92 (0.69–1.25)     469     61 1.04 (0.77–1.40) 0.99 (0.60–1.62) 
Acetaminophenb          
     Non-use 2,510 417 1.00 (Reference) 1.00 (Reference)  1,121 152 1.00 (Reference) 1.00 (Reference) 
     Any use    566   85 0.96 (0.78–1.19) 0.92 (0.72–1.19)     221   24 0.78 (0.51–1.19) 0.88 (0.57–1.37) 
Naproxenb          
     Non-use 2,922 474 1.00 (Reference) 1.00 (Reference)  1,287 162 1.00 (Reference) 1.00 (Reference) 
     Any use    154   28 1.22 (0.86–1.72) 1.14 (0.71–1.84)       55   14 1.83 (1.14–2.95) 1.51 (0.67–3.42) 
Aspirinb          
     Non-use 2,956 478 1.00 (Reference) 1.00 (Reference)  1,270 167 1.00 (Reference) 1.00 (Reference) 
     Any use    120   24 1.39 (0.96–2.00) 1.33 (0.81–2.18)       72     9 1.05 (0.55–1.99) 1.08 (0.56–2.09) 
a Models were adjusted for male age, BMI, household income, sugar sweetened beverage intake, alcohol intake, migraine headache, fever, and 
doing something to improve chances of conception.  
b Adjusted for all variables in footnote “a” and mutually adjusted for the other types of pain medications and reported indications for use. 
Note: Pain medication use was assessed during the 4 weeks before baseline. 
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Table 3.4 Continued. Baseline pain medication use and fecundability stratified by BMI 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Cycles Pregs FR (95% CI) FR (95% CI)a  Cycles Pregs FR (95% CI) FR (95% CI)a 
 BMI <30 kg/m2   BMI ≥30 kg/m2  
Any pain medication          
     Non-use 1,586 255 1.00 (Reference) 1.00 (Reference)     525   67 1.00 (Reference) 1.00 (Reference) 
     Any use 1,593 260 1.05 (0.90–1.23) 1.07 (0.92–1.26)     714   96 1.07 (0.80–1.44) 1.06 (0.79–1.43) 
Ibuprofenb           
     Non-use 2,015 326 1.00 (Reference) 1.00 (Reference)     758 105 1.00 (Reference) 1.00 (Reference) 
     Any use 1,164 189 1.04 (0.88–1.22) 1.13 (0.86–1.50)     481   58 0.86 (0.64–1.17) 0.79 (0.47–1.32) 
Acetaminophenb          
     Non-use 2,609 435 1.00 (Reference) 1.00 (Reference)  1,022 134 1.00 (Reference) 1.00 (Reference) 
     Any use   570   80 0.85 (0.68–1.06) 0.89 (0.66–1.22)     217   29 1.06 (0.73–1.54) 0.97 (0.67–1.39) 
Naproxenb          
     Non-use 3,052 483 1.00 (Reference) 1.00 (Reference)  1,157 153 1.00 (Reference) 1.00 (Reference) 
     Any use   127   32 1.52 (1.12–2.06) 1.67 (1.15–2.42)       82   10 1.07 (0.57–2.01) 0.89 (0.57–1.39) 
Aspirinb          
     Non-use 3,071 493 1.00 (Reference) 1.00 (Reference)  1,155 152 1.00 (Reference) 1.00 (Reference) 
     Any use    108   22 1.39 (0.95–2.03) 1.44 (0.92–2.26)       84   11 1.22 (0.68–2.17) 0.97 (0.62–1.51) 
FR=fecundability ratio 
a Models were adjusted for male age, BMI, household income, sugar sweetened beverage intake, alcohol intake, migraine headache, 
fever, and doing something to improve chances of conception.  
b Adjusted for all variables in footnote “a” and mutually adjusted for the other types of pain medications and reported indications for use. 
Note: Pain medication use was assessed during the 4 weeks before baseline. 
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Table 3.5: Baseline pain medication use and fecundability, restricted to users who 
reported headaches, muscle pains, or illness as indications for use 
Medication 
No. of No. of Unadjusted Adjusted 
Cycles Pregs FR (95% CI) FR (95% CI)a 
Headache 
Ibuprofen      
     Non-use 1,134    567 1.00 (Reference) 1.00 (Reference) 
     Any use 2,654 1,327 0.86 (0.63–1.18) 0.86 (0.62–1.19) 
Acetaminophen     
     Non-use 2,498 1,249 1.00 (Reference) 1.00 (Reference) 
     Any use 1,290    645 0.81 (0.61–1.08) 0.86 (0.63–1.16) 
Naproxen     
     Non-use 3,510 1,755 1.00 (Reference) 1.00 (Reference) 
     Any use    278    139 1.24 (0.80–1.93) 1.21 (0.80–1.85) 
Aspirin     
     Non-use 3,416 1,708 1.00 (Reference) 1.00 (Reference) 
     Any use    372    186 1.17 (0.76–1.73) 1.15 (0.77–1.73) 
Muscle Pain 
Ibuprofen      
     Non-use    402    201 1.00 (Reference) 1.00 (Reference) 
     Any use 1,324    662 0.99 (0.61–1.60) 0.93 (0.58–1.50) 
Acetaminophen     
     Non-use 1,164    582 1.00 (Reference) 1.00 (Reference) 
     Any use    562    281 0.95 (0.64–1.39) 0.93 (0.65–1.32) 
Naproxen     
     Non-use 1,492    746 1.00 (Reference) 1.00 (Reference) 
     Any use    234    117 1.41 (0.83–2.38) 1.22 (0.71–2.08) 
Aspirin     
     Non-use 1,640    820 1.00 (Reference) 1.00 (Reference) 
     Any use      86      43 1.28 (0.51–3.22) 1.27 (0.71–2.08) 
Illness 
Ibuprofen      
     Non-use   76     38 1.00 (Reference) 1.00 (Reference) 
     Any use 222   111 0.84 (0.40–1.75) 0.74 (0.33–1.61) 
Acetaminophen     
     Non-use 182     91 1.00 (Reference) 1.00 (Reference) 
     Any use 116     58 0.93 (0.42–2.09) 0.98 (0.56–1.70) 
Naproxen     
     Non-use 294   147 1.00 (Reference) 1.00 (Reference) 
     Any use     4       2 1.29 (0.34–4.90) 0.80 (0.32–2.05) 
Aspirin     
     Non-use 276   138 1.00 (Reference) 1.00 (Reference) 
     Any use   22     11 1.33 (0.39–4.45) 1.68 (0.23–12.08) 
FR=fecundability ratio 
a Models were adjusted for male age, BMI, household income, sugar sweetened beverage 
intake, alcohol intake, migraine headache, fever, and doing something to improve chances of 
conception. Models were mutually adjusted for the other types of pain medications. 
Note: Pain medication use was assessed during the 4 weeks before baseline. 
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Table 3.6 Baseline pain medication use and fecundability, restricted to users of single 
medications compared with ibuprofen use 
Medication 
No. of No. of Unadjusted Adjusted 
Cycles Pregs FR (95% CI) FR (95% CI)a 
     
Ibuprofen  1,259 196 1.00 (Reference) 1.00 (Reference) 
Acetaminophen    376   55 0.99 (0.77–1.28) 0.98 (0.80–1.21) 
Naproxen    127   28 1.36 (0.98–1.88) 1.25 (0.78–1.99) 
Aspirin      69   15 1.40 (0.90–2.18) 1.25 (0.75–2.08) 
     
FR=fecundability ratio 
a Models were adjusted for male age, BMI, household income, sugar sweetened beverage 
intake, alcohol intake, migraine headache, fever, and doing something to improve chances of 
conception. Results were also mutually adjusted for the other types of pain medications and 
reported indications for use.  
Note: Pain medication use was assessed during the 4 weeks before baseline. 
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4 Female Use of Pain Medication in Pregnancy and Spontaneous Abortion 
4.1 Introduction  
Spontaneous abortion (SAB), defined as the loss of pregnancy before 20 
weeks of gestation, is a common pregnancy outcome that affects approximately 
20% of clinically recognized pregnancies.1 About 50% of SABs are believed to 
have genetic cause.2,3 The mechanisms behind pregnancy loss are not fully 
understood, but systemic inflammation4 and reductions in uterine blood flow may 
contribute.5  
Women commonly use medication for pain and inflammation during 
pregnancy. In 2005, almost 60% of U.S. pregnant women used an analgesic 
during their first trimester. Acetaminophen use was most common (54.2%), 
followed by use of ibuprofen (16.0%), and aspirin (3.8%).6  
Over-the-counter pain medications generally relieve pain and inflammation 
by reducing prostaglandin (PG) synthesis,7–12 with the strength of effect varying 
by medication type7–12,18,19 and dose.9–12 The numerous PGs, differentiated by 
alphabetic/alphanumeric suffixes (e.g. PGA, PGF2), are found throughout the 
body and perform a variety of actions, including maintaining homeostasis13,14 and 
causing inflammation and pain.13 During pregnancy, there is a rise in PGA and 
PGI2 levels,15,16 and a decline in PGE and PGF2 levels.17 PGA and PGI2 act as 
vasodilators and reduced levels in pregnancy have been associated with 
hypertension, preeclampsia, and placental insufficiencies.18,19 Conversely, PGE2 
and PGF2a have vasoconstrictive properties, and increased levels may restrict 
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blood flow to the uterus20,21 and the placenta22,23 which could affect viability of the 
fetus.24  
While acetaminophen, a non-NSAID pain reliever, is widely considered the 
first-line treatment for pain during pregnancy,25,26 research on its effects during 
reproduction is sparse. The few available studies have indicated no increased 
risk of SAB after use.26–28  
Epidemiologic research examining the association of nonsteroidal anti-
inflammatory drugs (NSAIDs), including aspirin, ibuprofen, and naproxen, with 
SAB is conflicting. Some studies have found an increased risk of SAB after use 
of non-aspirin NSAIDs,27,29–31 while another found no increased risk after use of 
naproxen or ibuprofen.32 Early studies found an association between low-dose 
aspirin use and reduced risk of SAB.33,34 The more recent Effects of Aspirin in 
Gestation and Reproduction (EAGeR) randomized controlled trial, found no 
association between low-dose use and rate of clinical loss among women who 
experienced one to two previous pregnancy losses (HR=1.00, 95% CI: 0.73, 
1.36).36 When restricted to participants who experienced only one previous SAB 
that occurred during the past year, participants randomized to low-dose aspirin 
had a slightly higher live birth rate compared with placebo (HR=1.17, 95% CI: 
1.01–1.37).35 When examining primarily regular dose aspirin use, however, one 
observational post-conception cohort study found increased risk of SAB (HR=4.3, 
95% CI: 1.3–14.2) when aspirin was used around the time of conception.27  
Little is known about the effects of opioid use during pregnancy. While 
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there is evidence of other adverse birth outcomes,36,37 to our knowledge, there 
are no studies examining SAB after use of opioids during early pregnancy.  
Most prior studies of pain medication use in relation to SAB have been 
conducted using large administrative databases29,31,32 or post-conception 
pregnancy cohorts.26,27,33 Studies using administrative databases have 
substantial power to detect effects but are unable to examine over-the-counter 
medication use or control for confounding by variables unavailable in these 
databases (e.g. lifestyle factors). Lack of information on over-the-counter 
medication use may lead to substantial misclassification and preclude 
examination of infrequent use. More importantly, database studies and post-
conception cohorts may fail to capture SABs that occur before women visit 
healthcare providers, introducing bias if exposure is differentially related to timing 
of loss.  
  The present study prospectively examines the association between pain 
medication use during early pregnancy and SAB risk in three large prospective 
cohorts of women enrolled pre-pregnancy in Denmark, the U.S., and Canada. 
4.2 Methods 
4.2.1 Data Collection 
Data from three prospective cohort studies of pregnancy planners were 
combined for this analysis. 1) In Denmark, Snart Gravid (SG)38 (2007–2011) 
enrolled female pregnancy planners ages 18–49 years; 2) Snart Foraeldre (SF) 
(2011–2017) is an expansion of SG that includes male partners;39,40 3) In the 
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U.S. and Canada, Pregnancy Study Online (PRESTO)41 (2013–2017) enrolls 
female pregnancy planners ages 21–45 and their male partners. Recruitment 
and follow-up for SF and PRESTO are ongoing.  
These three studies have similar designs and data collection procedures. 
Participants were recruited primarily using advertisements on health-related 
websites and social media. Eligible women were in a relationship with a male 
partner, not pregnant, and not using contraception or fertility treatments.  
Questionnaires were administered online. Participants completed a 
questionnaire at baseline to report demographics, lifestyle factors, and medical 
history. Follow-up questionnaires were administered every two months until 
pregnancy or 12 months, whichever occurred first, to ascertain information on 
time-varying exposures (e.g. smoking status and alcohol consumption) and 
pregnancy status, identified by over 96% of participants using home pregnancy 
tests. Participants who conceived during follow-up completed an additional 
follow-up questionnaire during early (SG, SF, PRESTO; median 9 gestational 
weeks) and late (PRESTO; median 33 gestational weeks) pregnancy to ascertain 
data on pregnancy outcomes and exposures in pregnancy. Over 80% of 
participants completed at least one follow-up questionnaire.41,42 SF and SG 
participants provided their Civil Personal Registration (CPR) number, a ten-digit 
unique identifier assigned to all residents in Denmark43 allowing for linkage to 
pregnancy outcome information in the Danish National Registry of Patients 
(DNRP).  
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PRESTO participants were linked to birth registers in selected U.S. states 
and Canadian provinces (19.3%) to identify viable pregnancies among 
participants who were still pregnant at study completion or lost to follow-up after 
conception. Self-reported data on SABs were obtained from follow-up 
questionnaires.  
The Boston Medical Center institutional review board and the Danish Data 
Protection Board approved the study protocol and participants provided informed 
consent. 
4.2.2 Assessment of covariates 
  On the baseline questionnaire, participants reported data on 
sociodemographics, reproductive history, medical history, anthropometrics, and 
lifestyle factors. On the follow-up questionnaires, participants reported time-
varying data on lifestyle factors. Report of covariates occurred before the 
pregnancy outcome. BMI was calculated as weight (kg)/height (m)2.  
4.2.3 Assessment of SAB 
On each follow-up questionnaire, women were asked if they were 
currently pregnant (yes, no, don’t know) or if they experienced a pregnancy loss 
since the last questionnaire. Women who experienced an SAB, therapeutic 
abortion (TAB), or ectopic pregnancy reported the date and gestational week of 
pregnancy loss.  
To obtain additional information about pregnancy outcomes in Denmark, 
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we linked participant CPR numbers to records in the DNRP. The DNRP provides 
information on inpatient and outpatient diagnoses and services including labor 
and delivery, SAB, and TAB, and weeks of gestation at pregnancy loss. 
International Classification of Disease (ICD) 10th edition code DO03 was used to 
identify SABs and codes DO04-DO05 identified TABs. The positive predictive 
value for DNRP SAB diagnosis is excellent (97.4%).44  
In SG and SF, SAB was operationalized as 1) questionnaire report of a 
pregnancy loss at ≤20 gestational weeks and/or 2) questionnaire report of a 
viable pregnancy followed by a DNRP ICD-10 code for SAB at ≤20 gestational 
weeks, or 3) questionnaire report of a pregnancy and no subsequent ICD-10 
code for SAB, TAB, or labor and delivery (presumed SAB). Of 1,204 SABs 
observed in SG and SF, 446 (37.0%) were identified only in the DNRP, 431 
(35.8%) were identified only by questionnaire (i.e. early losses), and 151 (12.5%) 
were identified in both sources. Nearly 15% (N=176) of SG and SF participants 
reported a pregnancy on the early pregnancy questionnaire that was not found in 
the DNRP. We assumed these participants subsequently experienced an SAB 
and multiply imputed weeks of gestation as ≤12 because SABs later than 12 
weeks’ gestation typically would be identified in the DNRP. We conducted a 
sensitivity analysis excluding these women and observed similar results. 
4.2.4 Assessment of pain medication use 
Pain medication use was assessed at baseline and on each follow-up 
questionnaire. In SG and SF, participants were asked if they used any of 31 and 
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51 different pain medications during the past 4 weeks, respectively, and could 
check all that apply. In PRESTO, participants were asked if they used pain 
medication in the past 4 weeks. Users could indicate the names of up to 3 
medications using auto-complete text recognition software.45 For each reported 
medication, PRESTO and SF participants were asked how many pills they took 
during the past 4 weeks and SG participants were asked how many pills they 
used in categories (≤1, 2–5, 6–8 per week; 2, ≥3 per day). SG categories were 
converted to monthly intake using the midpoint of the category scaled to a 28 day 
period.  
Medications were categorized by active ingredient (acetaminophen, 
aspirin, ibuprofen, naproxen, opioids). Categories were not mutually exclusive; 
women who used medications with more than one active ingredient were 
considered users of both types. SG and SF questionnaires only included select 
opioid combination products; due to the incomplete ascertainment of exposure, 
opioids were only analyzed in PRESTO. 
At baseline and each follow-up, cumulative past-month dose was 
calculated as the total number of pills used during the past 4 weeks multiplied by 
the dose of the active ingredient in each pill, summed by active ingredient. The 
most common dose was used for medications that are available in multiple 
strengths. For example, if a participant indicated using 2 “Excedrin Migraine” 
pills, this would contribute 2 x 250 mg of acetaminophen and 2 x 250 mg of 
aspirin; if a participant reported 3 “ibuprofen,” this would contribute 3 x 200 mg of 
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ibuprofen, the most common strength. Dose was not analyzed for opioids due to 
the small number of users.  
The approximate date of conception was calculated as the first day of the 
last menstrual period +14 days. Use was assessed on any questionnaire 
completed between conception and 12 gestational weeks. Importantly, exposure 
information was reported before the pregnancy outcome was known, i.e. 
exposure information was not analyzed if it was reported concurrently with or 
after a pregnancy loss. To reduce potential for reverse causation, we only 
analyzed exposure on questionnaires that were completed between conception 
and >3 days before the reported date of SAB.46  
The majority of participants had one (52.2%) or two (11.7%) prospective 
exposure assessments during pregnancy; 36.1% of participants were missing 
exposure assessment during pregnancy. Figure 1 describes common scenarios 
for each number of exposure assessments. Participants who had one exposure 
assessment reported a pregnancy on a follow-up questionnaire, having 
conceived since the last data collection time point (scenarios A–B). Participants 
with two exposure assessments were pregnant at a prior follow-up but had not 
yet received a positive pregnancy test; they reported the pregnancy at the 
subsequent follow-up (scenarios C–D). Participants missing exposure 
assessment conceived and experienced an SAB between follow-up 
questionnaires (scenario F); or conceived after being lost to follow-up with a 
recorded live birth in the DNRP with no intervening pregnancy loss (SG & SF, 
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scenario E) (Figure 4.1).  
For each medication, a participant was considered exposed if she used ≥1 
pill during the pregnancy. Cumulative past-month dose was assigned as the 
reported monthly dose for participants with one prospective data collection time 
point during pregnancy, and the mean of reported monthly doses for participants 
with two prospective exposure assessments. For the 36.1% of women without 
exposure assessment during pregnancy, we used multiple imputation to 
complete missing exposure data in 5 datasets. We conducted the imputation 
separately for Danish and North American participants and included over 120 
variables in the imputation models, including all information on pre-conception 
pain medication use. We conducted a sensitivity analysis omitting all participants 
with missing exposure assessment. 
4.2.5 Exclusions 
This study was restricted to the PRESTO, SF, and SG participants who 
had a clinically detectable pregnancy as reported on follow-up questionnaires or 
in the DNRP. Exclusions by study are detailed in Figure 4.2. 
4.2.6 Data analysis 
We conducted a time-to-event analysis using gestational weeks as the 
time scale. We first examined the association between use of acetaminophen, 
aspirin, ibuprofen, naproxen, or opioids (PRESTO) during pregnancy and SAB. 
We then examined the association between cumulative monthly dose and SAB, 
  
67 
grouped into two categories based on the distribution of reported use.  
We used Cox proportional hazards regression models using gestational 
weeks as the time scale to estimate hazard ratios (HR) and 95% confidence 
intervals (CI), using the exact option in PROC PHREG to account for tied event 
times.47,48 The HR is approximately equal to average per-week risk of SAB 
comparing users of a specific pain medication with non-users of that medication. 
Participants were censored at gestational week of SAB, TAB, last follow-up, or 
20 weeks, whichever occurred first. Proportional hazards was confirmed using 
log survivor plots. 
Models were adjusted for potential confounders selected a priori based on 
the literature and a directed acyclic graph.  These included study cohort (SG, SF, 
PRESTO), age (<25, 25–29, 30–34, 35–39, ≥40 years), education (≤12, 13–15, 
16, ≥17 years), income (< versus ≥ 50,000 USD/300,000 DKK per year), non-
Hispanic white (yes versus no), BMI (<18.5, 18.5–24, 25–29, ≥30 kg/m2), 
diagnosis of migraine headaches (yes versus no), diabetes (yes versus no), 
uterine leiomyoma (yes versus no) or thyroid disease (yes versus no), and 
cigarette smoking (yes versus no), alcohol use (yes versus no), or antibiotic use 
(yes versus no) during pregnancy (proxy for fever or infection). Models were 
mutually adjusted for the other types of pain medications.  
To examine effect measure modification, results were examined 
separately by age (<30 versus ≥30 years), time to pregnancy (<6 versus 3–≥6 
cycles), BMI (<30 versus ≥30 kg/m2) and history of SAB (yes versus no). To 
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identify any impact of difference in methodology by cohort, we examined results 
separately by study (SG, SF, PRESTO). Further, because the etiology of 
pregnancy loss may differ by weeks of gestation at loss,49 we stratified by timing 
of loss (<8  versus ≥8 weeks). Next, we compared use of each pain medication 
with non-use of any pain medication by restricting to women who used only one 
type of pain medication during pregnancy or who did not use pain-relievers. To 
control for residual confounding by indication, we then compared users of aspirin, 
ibuprofen or naproxen to users of the most common medication, acetaminophen, 
as these medications are often used for the same indications. Finally, because 
we were unable to examine time-varying medication use to avoid potential 
immortal time bias that occurs when viable pregnancies have more time to 
accrue exposure,32 we conducted a sensitivity analysis to reduce the probability 
of this bias by limiting exposure assessment to any data collection time point that 
occurred at <8 weeks of gestation, instead of the <12 weeks of gestation used in 
our main analyses.  
Thirty seven percent of participants were missing data on pain-reliever use 
during pregnancy. Missing covariate data ranged from <3% (age, race, 
education, BMI, migraine headaches) to 34% (smoking during pregnancy), with 
the exception of antibiotic use during pregnancy, which was missing for 66% of 
participants. Antibiotic use was not collected in SG and was thus “missing at 
random”.50 We used PROC MI to impute missing values in five imputed datasets 
and PROC MIANALYZE to combine coefficient and standard error estimates.48  
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4.3 Results 
 Among 13,901 pregnancy planners, we identified 9,196 pregnancies 
conceived without the use of fertility treatments and 1,597 SABs (Overall: 17.4%, 
SG: 17.5%, SF: 18.0%, PRESTO: 16.5%). Nearly half (45.1%) of pregnancies 
were exposed to one or more pain medications before 12 gestational weeks, 
most commonly acetaminophen (37.0%) or ibuprofen (17.5%) and less 
commonly aspirin (5.7%), opioids (3.7%, PRESTO) or naproxen (1.6%). Overall, 
cumulative monthly dose was low; the median dose was 2,000 mg (IQR: 500–
3,500) for acetaminophen, 400 mg (IQR: 200–1,400) for ibuprofen, 250 mg (IQR: 
250–3,500) for aspirin, 220 mg (IQR: 220–660) for naproxen, and 1 pill (PRESTO 
IQR: 1–2) for opioids.  
Pain medication use, especially use of naproxen or ibuprofen, was more 
common in PRESTO compared with SG and SF. Pain medication use during 
pregnancy was associated with lower educational attainment, use of alcohol or 
tobacco during pregnancy, and indications such as migraine headache or 
antibiotic use during pregnancy (i.e., proxy for fever or infection). Diagnoses of 
uterine leiomyoma or thyroid disease were more common among naproxen and 
opioid users, and opioid users were more likely to have a higher BMI and a 
history of SAB, compared with non-users of these respective medications (Table 
4.1). 
 After adjusting for potential confounders, the HRs for pain medication use 
and SAB were 1.04 (95% CI: 0.82–1.31) for acetaminophen, 1.06 (95% CI: 0.81–
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1.39) for aspirin, 1.28 (95% CI: 1.11–1.47) for ibuprofen, 1.26 (95% CI: 0.61–
2.57) for naproxen, and 1.66 (95% CI: 0.85–3.24) for opioids (PRESTO), 
compared with non-users of each respective medication. We observed consistent 
results after excluding women with missing exposure data (Table 4.2). We did 
not observe dose response relations, apart from naproxen, for which there were 
only 8 events in the high dose category, however, results were not consistent 
when restricted to participants with exposure assessment during pregnancy 
(Table 4.3). 
 SAB risk was higher for ibuprofen users <30 years (HR=1.55, 95% CI: 
1.28–1.88) than for ≥30 years (HR=1.04, 95% CI: 0.84–1.28), compared with 
non-users of ibuprofen. Further, ibuprofen users had increased risk of early 
(HR=1.44, 95% CI: 1.19–1.73) but not late (HR=1.05, 95% CI: 0.85–1.30) SAB 
compared with non-users. For no other pain-relieving medications did the risk of 
SAB appear to differ by gestational week.  Aspirin use was associated with 
increased risk of SAB among women without a history of SAB (HR=1.28, 95% CI: 
0.90–1.82) but not among women with a history of SAB (HR=0.97, 95% CI: 0.52–
1.80) (Table 4.4).  
After stratifying by BMI (Table 4.4), time-to-pregnancy (Table 4.4), and 
cohort (Table 4.5), results were consistent with our overall findings. When 
restricted to users of a single medication, or to participants with exposure 
assessment before 8 gestational weeks, the results did not change appreciably 
(Table 4.6).  
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4.4 Discussion 
 In this large prospective cohort of Danish and North American women 
recruited during preconception, we found that use of ibuprofen, opioids, or 
naproxen before 12 weeks of gestation was associated with a small increased 
risk of SAB, after controlling for demographics, common indications for use of 
pain medications, and other covariates, although numbers of naproxen and 
opioid users were small. Overall, low cumulative dose of acetaminophen or 
aspirin did not affected risk of SAB. Among women without a history of SAB, 
aspirin use was associated with a slight increase in risk of SAB. 
  The lack of association between acetaminophen use and SAB risk is 
consistent with prior literature.27,28 It is important to note, however, that recent 
studies have suggested possible associations between in-utero exposure to 
acetaminophen and adverse infant and childhood outcomes including 
neurodevelopmental problems,51–53 asthma,54,55 and reduced anogenital 
distance56,57 in male offspring. 
 Results for ibuprofen and naproxen are consistent with most,27,29,30 but not 
all,32 previous studies that found an increased risk of SAB among users of non-
aspirin NSAIDs. Ibuprofen and naproxen use, via alterations in PG synthesis,8,12 
may upset the balance of PGA and PGI2 upregulation15,16 and PGE and PGF2 
downregulation17 needed to sustain pregnancy.18–24 Ibuprofen was associated 
with increased risk of early (<8 gestational weeks) but not late (≥8 gestational 
weeks) pregnancy loss. Because ibuprofen is not recommended for pain-relief 
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during pregnancy,25,26 use may have occurred before the women knew they were 
pregnant, thereby increasing the risk of early loss proximate to exposure. 
Overall, we did not observe any appreciable association between aspirin 
use and SAB risk, overall and by dose, and specifically among women with a 
history of SAB. Our results are consistent with the EAGeR randomized trial 
finding similar results when examining low-dose aspirin use among women with a 
prior SAB.35,58 Our result of slightly increased risk of SAB among aspirin users 
without a history of SAB was consistent with the Li et al. study, which examined 
regular-dose aspirin use in a post-conception cohort. It is possible that regular- 
but not low-dose aspirin use increases risk of SAB. 
Little is known about the effect of opioid use during pregnancy on SAB 
risk. Our data showed an increased risk of SAB among PRESTO participants 
who reported opioid use. Bateman et al. found that in the U.S. opioids are 
prescribed during pregnancy for symptoms such as back pain, abdominal pain, 
joint pain, cough, or migraine headaches.59 They found a high prevalence of 
opioid prescriptions for abdominal pain (31.9%),59 a common symptom of SAB, 
indicating that reverse causation may explain the increase in risk we observed. 
To reduce this bias, we only assessed exposures reported on questionnaires 
completed >3 days before the reported date of SAB; however, this step may not 
have fully eliminated reverse causation. For example, if a woman took a 
medication for SAB pain and inaccurately recorded a later date at SAB, she may 
be incorrectly classified as a user. Since the early 2000s, the U.S. has 
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experienced a significant increase in opioid abuse and dependence.59,60  There 
may be lifestyle factors associated with opioid abuse that increase the risk of 
SAB. For example, opioid users may have poor nutrition61 or use illicit drugs,62 
which could increase SAB risk. 
 This study has several limitations. Primarily, due to the timing of follow-up 
questionnaires, pregnancy exposure information was not collected for all 
participants. Using multiple imputation allowed us to address missing data and 
avoid a selection bias that could occur if we excluded these participants.  
Secondly, exposure misclassification is also likely. We relied on participant 
report of pain reliever use, which was likely underreported or recalled with error. 
Exposure was most often assessed once during pregnancy and the timing, 
frequency, and dose of medication use could have varied greatly within 12 weeks 
of gestation. Because exposure was ascertained before the pregnancy outcome 
was known, these sources of exposure misclassification are unlikely to be 
differential. As such, we would expect our effect estimates to be biased towards 
the null, with the exception of the intermediate dose group, which could be 
biased in either direction. While we limited exposure assessment to <3 days 
before the date of SAB, if this date was incorrectly identified as a later date, 
differential misclassification of exposure is possible. This would result in an 
upward bias and could partially explain the increased risk of SAB observed 
among ibuprofen, opioid, and naproxen users compared with non-users. Further, 
while pain medication use during pregnancy was common, participants mainly 
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used low cumulative doses, precluding the interpretation of differences by dose. 
Likewise, aspirin, naproxen and opioid use was uncommon and opioid use could 
only be analyzed in PRESTO, thereby limiting our precision.  
We assessed exposure between conception and 12 weeks of gestation, 
however, viable pregnancies often had a greater amount of time to be exposed to 
pain medications compared with pregnancies ending in SABs, possibly creating a 
downward bias.32 This potential bias would not explain the increased risk of SAB 
observed after ibuprofen, opioid, or naproxen use.  Further, it is likely that we 
failed to observe early losses that occurred before pregnancy detection. 
Additionally while we had Danish registry data to ascertain SABs not reported on 
questionnaires, this information was unavailable in the PRESTO cohort. 
Nevertheless, we observed a similar risk of SAB in Denmark (17.7%) and North 
America (16.5%), indicating that the use of different sources of outcome 
information was unlikely to introduce appreciable bias. Further, we had more 
complete ascertainment of SABs compared with many post-conception cohorts 
(e.g. 4.8%,26 6.3%33) or studies exclusively using administrative databases (e.g. 
9.9%32). Furthermore, some residual confounding by indication is likely because 
we did not know the specific indication for use. We assessed indication more 
generally using other questionnaire items (e.g. migraine headache, antibiotics as 
a proxy for infection), however, we were not able to adjust for indications such as 
abdominal cramping, which could lead to an upward bias.  
Our study indicates that low cumulative dose use of ibuprofen, opioids, 
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and naproxen during pregnancy may be associated with a small increased risk of 
SAB, though numbers of naproxen and opioid users were low. Overall, low 
cumulative dose aspirin or acetaminophen use was not appreciably associated 
with SAB.  
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Figure 4.1 Scenarios for exposure assessments during pregnancy, by number of prospective assessments available for 
analysis 
 
SAB=Spontaneous abortion 
Note 1: Not drawn to scale. Follow-up questionnaires were administered every 8 weeks until reported pregnancy, then during early pregnancy. 
Note 2: Solid horizontal line denotes pregnancy 
Note 3: Viable pregnancies were censored at 20 weeks. 
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Figure 4.2 Flow chart of enrollment and exclusions, Snart Gravid, Snart Foraeldre and PRESTO, 2007–2017    
. 
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Table 4.1 Characteristics of participants by pain medication use before 12 gestational weeks, Snart Gravid, Snart Foraeldre and 
PRESTO (N=9,196), 2007–2017  
 Pain Medication Use  Type of Medication Use  
 No Yes  Acetaminophen  Aspirin  Ibuprofen Naproxen Opioids† 
Number of Participants N (%) 5,052 
(54.9) 
4,144 
(45.1) 
 3,398 
(37.0) 
520 
(5.7) 
1,612 
(17.5) 
146 
(1.6) 
89 
(3.7) 
Cohort         
          Snart Gravid, % 49.0 50.2  52.3 53.1 47.3 27.4 -- 
          Snart Foraeldre, % 27.5 21.0  22.9 21.4 20.1   9.6 -- 
          PRESTO, % 23.5 28.8  24.8 25.6 32.6 63.0 100.0 
Age (years), mean 28.7 28.6  28.6 28.8 28.7 28.2 28.6 
Non-Hispanic White, % 96.4 96.3  96.9 95.4 95.7 92.2 75.2 
Annual household income <50,000 
USD/<300,000 DKK, % 
15.4 16.0  16.0 16.6 17.3 15.4 25.0 
<College degree, % 31.6 35.4  36.0 38.6 36.2 34.7 32.4 
BMI (kg/m2), mean 24.2 25.4  25.4 25.2 25.6 26.9 28.1 
Physical activity (MET-hrs/wk), mean 41.7 36.5  36.4 34.6 37.3 38.9 34.7 
Alcohol use during pregnancy, % 41.6 64.0  61.6 80.8 79.1 69.2 64.9 
Smoked during pregnancy, %   7.9 13.8  14.0 18.4 15.8 11.1 10.0 
Multivitamin supplement use, % 81.9 83.6  83.8 80.3 83.2 85.1 71.3 
Antibiotic use during pregnancy, %   6.3 20.5  21.4 37.8 25.1 44.5 31.3 
History of SAB, % 15.3 16.5  16.8 18.5 16.0 16.6 26.7 
Migraine headaches, % 30.2 47.6  49.9 52.6 45.7 28.5 29.6 
Diabetes, %   0.9   1.6    1.8   2.1   2.1 <2.0   0.0 
Uterine leiomyoma, %   1.4   2.2    2.5   4.4   2.0   5.9   6.8 
Thyroid disease, %   2.6   3.5    3.3   3.0   4.1   5.4   7.4 
Time to pregnancy ≥6 months, % 45.7 48.8  49.0 53.1 52.1 49.8 58.8 
Regular period, % 69.9 69.7  70.3 72.4 70.0 62.0 57.1 
Did something to improve chances of 
conception, % 
61.2 63.9  64.0 64.2 64.4 73.0 71.2 
USD = U.S. dollars, DKK = Danish kroner, MET = metabolic equivalent of task 
† Data from PRESTO are presented. SG and SF did not have complete ascertainment of opioids on participant questionnaires. 
Note 1. All characteristics except for age and cohort are age-standardized to the study population at baseline. 
Note 2. Column percentages are displayed  
Note 3. Medication categories are not mutually exclusive. 
Note 4. Antibiotic use was not collected in SG. Multiple imputation was used to complete missing data. 
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Table 4.2 Pain medication use before 12 gestational weeks and spontaneous abortion, Snart Gravid, Snart Foraeldre and 
PRESTO, 2007–2017  
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI) a  Pregs SAB HR (95% CI) HR (95% CI) a 
 Full cohort using multiple imputation to complete 
missing exposure information (N=9,196) 
 Restricted to participants with exposure 
assessment during pregnancy (N=5,876) 
          
Any pain medication          
     Non-use 5,052 772 1.00 (Reference) 1.00 (Reference)  3,473 243 1.00 (Reference) 1.00 (Reference) 
     Any use 4,144 825 1.37 (1.09–1.71) 1.24 (0.99–1.55)  2,403 251 1.54 (1.29–1.83) 1.26 (1.05–1.52) 
Acetaminophen          
     Non-use 5798 940 1.00 (Reference) 1.00 (Reference)  3,916 322 1.00 (Reference) 1.00 (Reference) 
     Any use 3398 657 1.08 (0.85–1.36) 1.04 (0.82–1.31)  1,960 172 0.98 (0.81–1.19) 0.93 (0.77–1.13) 
Aspirin          
     Non-use 8,676 1,479 1.00 (Reference) 1.00 (Reference)  5,657 469 1.00 (Reference) 1.00 (Reference) 
     Any use    520 118 1.11 (0.85–1.45) 1.06 (0.81–1.39)     219   25 1.03 (0.64–1.68) 0.90 (0.57–1.45) 
Ibuprofen           
     Non-use 7,584 1,223 1.00 (Reference) 1.00 (Reference)  5,098 392 1.00 (Reference) 1.00 (Reference) 
     Any use 1,612 374 1.42 (1.23–1.64) 1.28 (1.11–1.47)     778 102 1.75 (1.39–2.18) 1.29 (1.02–1.63) 
Naproxen          
     Non-use 9,050 1,560 1.00 (Reference) 1.00 (Reference)  5,828 487 1.00 (Reference) 1.00 (Reference) 
     Any use    146   37 1.25 (0.62–2.52) 1.26 (0.61–2.57)       48    7 1.60 (0.75–3.41) 1.24 (0.58–2.65) 
Opioids†          
     Non-use 2,291    368 1.00 (Reference) 1.00 (Reference)  1,678 170 1.00 (Reference) 1.00 (Reference) 
     Any use      89      25 1.61 (0.90–2.88) 1.66 (0.85–3.24)       30     7 2.19 (1.01–4.75) 2.07 (0.93–4.61) 
          
SAB=spontaneous abortion, HR=hazard ratio 
† Opioids analyses were restricted to PRESTO participants. SG and SF did not have complete ascertainment of opioids on participant 
questionnaires. 
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.3 Cumulative monthly dose of pain medication exposure before 12 gestational weeks and spontaneous abortion, Snart 
Gravid, Snart Foraeldre and PRESTO, 2007–2017 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI) HR (95% CI)a  Pregs SAB HR (95% CI) HR (95% CI)a 
 Full cohort using multiple imputation to complete 
missing exposure information (N=9,196) 
 Restricted to participants with exposure 
assessment during pregnancy (N=5,876)  
          
Non-use 5,052    772 1.00 (Reference) 1.00 (Reference)  3,427   239 1.00 (Reference) 1.00 (Reference) 
Any use          
       Low exposure 2,192    488 1.57 (1.27–1.94) 1.42 (1.15–1.75)     900      93 1.60 (1.26–2.03) 1.22 (0.94–1.59) 
       Moderate exposure 2,020    349 1.16 (0.91–1.47) 1.05 (0.82–1.34)  1,549    162 1.50 (1.23–1.83) 1.28 (1.02–1.59) 
 Acetaminophen (mg)          
     Non-use 5798    940 1.00 (Reference) 1.00 (Reference)  1,960    172 1.00 (Reference) 1.00 (Reference) 
     <3,000 1,855    408 1.22 (0.97–1.55) 1.17 (0.93–1.49)     797      70 1.05 (0.80–1.36) 0.93 (0.71–1.23) 
     ≥3,000 1,543    249 0.92 (0.71–1.18) 0.88 (0.68–1.14)  1,163    102 0.94 (0.75–1.18) 0.93 (0.72–1.19) 
Aspirin (mg)          
     Non-use 8,676 1,479 1.00 (Reference) 1.00 (Reference)  5,657    469 1.00 (Reference) 1.00 (Reference) 
     <500    295      84 1.39 (0.98–1.96) 1.36 (0.95–1.94)       14        0 -- -- 
     ≥500    225      34 0.76 (0.52–1.10) 0.70 (0.48–1.03)     205      25 1.11 (0.68–1.82) 0.98 (0.61–1.58) 
Ibuprofen (mg)          
     Non-use 7,584 1,223 1.00 (Reference) 1.00 (Reference)  5,098   392 1.00 (Reference) 1.00 (Reference) 
     <1,000 1,066    274 1.58 (1.35–1.86) 1.43 (1.23–1.68)     322      47 1.98 (1.45–2.69) 1.38 (0.99–1.92) 
     ≥1,000    546    100 1.11 (0.88–1.41) 1.00 (0.78–1.27)     456      55 1.58 (1.19–2.11) 1.23 (0.91–1.65) 
Naproxen (mg)          
     Non-use 9,050 1,560 1.00 (Reference) 1.00 (Reference)  5,828    487 1.00 (Reference) 1.00 (Reference) 
     <500    110      29 1.21 (0.54–2.72) 1.21 (0.53–2.79)       19      ≤3 0.51 (0.07–3.69) 0.42 (0.06–3.00) 
     ≥500      36        8 1.34 (0.63–2.86) 1.34 (0.63–2.87)       29        6 2.48 (1.11–5.57) 1.84 (0.81–4.16) 
          
HR=hazard ratio 
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.4 Pain medication use before 12 gestational weeks and spontaneous abortion, stratified by age, Snart Gravid, Snart 
Foraeldre and PRESTO, 2007–2017 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a  Pregs SAB HR (95% CI) HR (95% CI)a 
 Age<30  Age≥30  
          
Any pain medication          
     Non-use 3,035 390  1.00 (Reference)  1.00 (Reference)  2,017 382  1.00 (Reference)  1.00 (Reference) 
     Any use 2,458 440 1.48 (1.13–1.93) 1.33 (1.01–1.75)  1,686 385 1.24 (1.01–1.53) 1.16 (0.94–1.43) 
Acetaminophen          
     Non-use 3,471 484  1.00 (Reference)  1.00 (Reference)  2,327 456  1.00 (Reference)  1.00 (Reference) 
     Any use 1,676 346 1.07 (0.83–1.38) 1.01 (0.77–1.33)  1,376 311 1.08 (0.84–1.40) 1.06 (0.82–1.39) 
Aspirin          
     Non-use 5,194 778  1.00 (Reference)  1.00 (Reference)  3,482 701  1.00 (Reference)  1.00 (Reference) 
     Any use    299   52 1.01 (0.69–1.49) 0.98 (0.66–1.45)     221   66 1.23 (0.81–1.86) 1.14 (0.77–1.70) 
Ibuprofen           
     Non-use 4,550 615  1.00 (Reference)  1.00 (Reference)  3,034 608  1.00 (Reference)  1.00 (Reference) 
     Any use   943 215 1.72 (1.43–2.08) 1.55 (1.28–1.88)     669 159 1.12 (0.92–1.37) 1.04 (0.84–1.28) 
Naproxen          
     Non-use 5,399 813  1.00 (Reference)  1.00 (Reference)  3,651 747  1.00 (Reference)  1.00 (Reference) 
     Any use      94   17 1.08 (0.40–2.89) 1.04 (0.37–2.91)       52   20 1.49 (0.75–2.96) 1.44 (0.72–2.90) 
          
HR=hazard ratio  
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.4 Continued. Pain medication use before 12 gestational weeks and spontaneous abortion, stratified by time to 
conception, Snart Gravid, Snart Foraeldre and PRESTO, 2007–2017 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a  Pregs SAB HR (95% CI) HR (95% CI)a 
 Time to conception <6 cycles  Time to conception ≥6 cycles  
          
Any pain medication          
     Non-use 2,744 410  1.00 (Reference)  1.00 (Reference)   2,308 362  1.00 (Reference)  1.00 (Reference) 
     Any use 2,121 387 1.34 (1.03–1.75) 1.25 (0.97–1.62)   2,023 438 1.37 (1.08–1.75) 1.24 (0.97–1.57) 
Acetaminophen          
     Non-use 3,134 489  1.00 (Reference)  1.00 (Reference)  2,664 451  1.00 (Reference)  1.00 (Reference) 
     Any use 1,731 308 1.12 (0.90–1.38) 1.08 (0.88–1.34)  1,667 349 1.03 (0.75–1.43) 1.00 (0.73–1.37) 
Aspirin          
     Non-use 4,622 747  1.00 (Reference)  1.00 (Reference)  4,054 732  1.00 (Reference)  1.00 (Reference) 
     Any use    243   50 1.08 (0.67–1.75) 1.02 (0.63–1.67)     277   68 1.12 (0.77–1.62) 1.07 (0.75–1.53) 
Ibuprofen           
     Non-use 4,094 635  1.00 (Reference)  1.00 (Reference)  3,490 588  1.00 (Reference)  1.00 (Reference) 
     Any use    771 162 1.34 (1.05–1.73) 1.24 (0.98–1.57)     841 212 1.45 (1.22–1.74) 1.32 (1.09–1.59) 
Naproxen          
     Non-use 4,792 775  1.00 (Reference)  1.00 (Reference)  4,258 785  1.00 (Reference)  1.00 (Reference) 
     Any use     73   22 1.37 (0.46–4.09) 1.42 (0.48–4.26)       73   15 1.14 (0.58–2.26) 1.11 (0.56–2.19) 
          
HR=hazard ratio 
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.4 Continued. Pain medication use before 12 gestational weeks and spontaneous abortion, stratified by BMI, Snart 
Gravid, Snart Foraeldre and PRESTO, 2007–2017 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a  Pregs SAB HR (95% CI) HR (95% CI)a 
 BMI <30 kg/m2   BMI ≥30 kg/m2  
          
Any pain medication          
     Non-use 4,475    677  1.00 (Reference)  1.00 (Reference)     577   95  1.00 (Reference)  1.00 (Reference) 
     Any use 3,421    675 1.37 (1.09–1.71) 1.23 (1.00–1.53)     723 150 1.28 (0.82–1.99) 1.25 (0.76–2.06) 
Acetaminophen          
     Non-use 5,100    812  1.00 (Reference)  1.00 (Reference)     698 128  1.00 (Reference)  1.00 (Reference) 
     Any use 2,796    540 1.09 (0.86–1.39) 1.05 (0.83–1.34)     602 117 0.97 (0.65–1.45) 0.97 (0.63–1.49) 
Aspirin          
     Non-use 7,463 1,254  1.00 (Reference)  1.00 (Reference)  1,213 225  1.00 (Reference)  1.00 (Reference) 
     Any use    433      98 1.16 (0.88–1.54) 1.10 (0.83–1.47)       87   20 0.91 (0.50–1.65) 0.86 (0.47–1.57) 
Ibuprofen           
     Non-use 6,590 1,056  1.00 (Reference)  1.00 (Reference)     994 167  1.00 (Reference)  1.00 (Reference) 
     Any use 1,306    296 1.42 (1.18–1.70) 1.27 (1.06–1.51)     306   78 1.36 (0.94–1.98) 1.32 (0.84–2.08) 
Naproxen          
     Non-use 7,783 1,327  1.00 (Reference)  1.00 (Reference)  1,267 233  1.00 (Reference)  1.00 (Reference) 
     Any use    113      25 1.22 (0.57–2.62) 1.19 (0.57–2.49)       33   12 1.35 (0.53–3.46) 1.48 (0.46–4.77) 
          
HR=hazard ratio  
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.4 Continued. Pain medication use before 12 gestational weeks and spontaneous abortion, stratified by timing of 
pregnancy loss, Snart Gravid, Snart Foraeldre and PRESTO, 2007–2017 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a  Pregs SAB HR (95% CI) HR (95% CI)a 
 Pregnancy loss <8 weeks   Pregnancy loss ≥ 8 weeks 
          
Any pain medication          
     Non-use 4,671 391  1.00 (Reference)  1.00 (Reference)  4,661 381  1.00 (Reference)  1.00 (Reference) 
     Any use 3,812 493 1.55 (1.12–2.15) 1.37 (1.00–1.88)  3,651 332 1.17 (0.94–1.46) 1.09 (0.87–1.37) 
Acetaminophen          
     Non-use 5,340 482  1.00 (Reference)  1.00 (Reference)  5,316 458  1.00 (Reference)  1.00 (Reference) 
     Any use 3,143 402 1.17 (0.84–1.62) 1.12 (0.81–1.56)  2,996 255 0.96 (0.73–1.27) 0.93 (0.70–1.23) 
Aspirin          
     Non-use 8,012 815  1.00 (Reference)  1.00 (Reference)  7,861 664  1.00 (Reference)  1.00 (Reference) 
     Any use    471   69 1.07 (0.71–1.60) 1.02 (0.68–1.53)     451  49 1.19 (0.78–1.82) 1.15 (0.74–1.79) 
Ibuprofen           
     Non-use 7,005 644  1.00 (Reference)  1.00 (Reference)  6,940 579  1.00 (Reference)  1.00 (Reference) 
     Any use 1,478 240 1.64 (1.35–1.98) 1.44 (1.19–1.73)  1,372 134 1.14 (0.92–1.40) 1.05 (0.85–1.30) 
Naproxen          
     Non-use 8,352 862  1.00 (Reference)  1.00 (Reference)  8,188 698  1.00 (Reference)  1.00 (Reference) 
     Any use    131   22 1.28 (0.58–2.82) 1.22 (0.52–2.87)     124   15 1.23 (0.59–2.55) 1.33 (0.64–2.76) 
          
HR=hazard ratio  
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.4 Continued. Pain medication use before 12 gestational weeks and spontaneous abortion, stratified by history of SAB, 
Snart Gravid, Snart Foraeldre and PRESTO, 2007–2017 
 No. of No. of Unadjusted Adjusted  No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a  Pregs SAB HR (95% CI) HR (95% CI)a 
 No history of SAB    History of SAB 
          
Any pain medication          
     Non-use 4,177    588  1.00 (Reference)  1.00 (Reference)     751 155  1.00 (Reference)  1.00 (Reference) 
     Any use 3,563    668 1.41 (1.21–1.64) 1.34 (1.13–1.58)     705 186 1.29 (0.97–1.70) 1.35 (1.01–1.80) 
Acetaminophen          
     Non-use 4,798    730  1.00 (Reference)  1.00 (Reference)     863 182  1.00 (Reference)  1.00 (Reference) 
     Any use 2,942    526 1.05 (0.87–1.27) 1.04 (0.86–1.25)     593 159 1.07 (0.76–1.50) 1.17 (0.84–1.65) 
Aspirin          
     Non-use 7,282 1,145  1.00 (Reference)  1.00 (Reference)  1,351 311  1.00 (Reference)  1.00 (Reference) 
     Any use    458    111 1.30 (0.92–1.82) 1.28 (0.90–1.82)        105   30 0.97 (0.56–1.65) 0.97 (0.52–1.80) 
Ibuprofen           
     Non-use 6,359    955  1.00 (Reference)  1.00 (Reference)  1,193 275  1.00 (Reference)  1.00 (Reference) 
     Any use 1,381    301 1.59 (1.26–2.00) 1.50 (1.19–1.90)     263   66 1.22 (0.74–2.00) 1.17 (0.77–1.77) 
Naproxen          
     Non-use 7,616 1,232  1.00 (Reference)  1.00 (Reference)  1,432 333  1.00 (Reference)  1.00 (Reference) 
     Any use    124      24 1.03 (0.58–1.82) 1.07 (0.58–1.98)       24     8 1.30 (0.43–3.90) 1.54 (0.48–4.94) 
          
HR=hazard ratio  
a Models were adjusted for cohort, age, non-Hispanic white, income, education, BMI, use of cigarettes, alcohol, or antibiotics during 
pregnancy, diagnosis of migraine headaches, diabetes, uterine leiomyoma, or thyroid disease. Medication specific results were also 
mutually adjusted for the other types of pain medications. 
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Table 4.5 Pain medication use before 12 gestational weeks and spontaneous abortion, 
stratified by cohort, 2007–2017 
 No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a 
   SG  
     
Any pain medication     
     Non-use 2,473 379  1.00 (Reference)  1.00 (Reference) 
     Any use 2,081 418 1.36 (1.11–1.66) 1.26 (1.03–1.54) 
Acetaminophen     
     Non-use 2,778 448  1.00 (Reference)  1.00 (Reference) 
     Any use 1,776 349 1.11 (0.89–1.40) 1.08 (0.85–1.36) 
Aspirin     
     Non-use 4,278 740  1.00 (Reference)  1.00 (Reference) 
     Any use    276   57 1.09 (0.71–1.67) 1.04 (0.67–1.63) 
Ibuprofen      
     Non-use 3,791 620  1.00 (Reference)  1.00 (Reference) 
     Any use    763 177 1.34 (1.02–1.76) 1.23 (0.94–1.60) 
Naproxen     
     Non-use 4,514 786  1.00 (Reference)  1.00 (Reference) 
     Any use      40   11 1.29 (0.29–5.66) 1.37 (0.31–6.09) 
     
   SF  
     
Any pain medication     
     Non-use 1,391 216  1.00 (Reference)  1.00 (Reference) 
     Any use    871 191 1.54 (0.94–2.53) 1.25 (0.80–1.96) 
Acetaminophen     
     Non-use 1,484 240  1.00 (Reference)  1.00 (Reference) 
     Any use    778 167 1.12 (0.71–1.76) 1.00 (0.68–1.49) 
Aspirin     
     Non-use 2,151 369  1.00 (Reference)  1.00 (Reference) 
     Any use    111   38 1.89 (1.10–3.24) 1.60 (0.93–2.75) 
Ibuprofen      
     Non-use 1,938 314  1.00 (Reference)  1.00 (Reference) 
     Any use    324   93 1.65 (1.21–2.26) 1.45 (1.01–2.06) 
Naproxen     
     Non-use 2,248 402  1.00 (Reference)  1.00 (Reference) 
     Any use      14     5 1.64 (0.41–6.50) 1.50 (0.42–5.40) 
     
HR=hazard ratio 
a Models were adjusted for age, non-Hispanic white, income, education, BMI, use of cigarettes, 
alcohol, or antibiotics during pregnancy, diagnosis of migraine headaches, diabetes, uterine 
leiomyoma, or thyroid disease. Medication specific results were also mutually adjusted for the 
other types of pain medications.
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Table 4.5 Continued. Pain medication use before 12 gestational weeks and spontaneous 
abortion, stratified by cohort, 2007–2017 
 No. of No. of Unadjusted Adjusted 
Medication Pregs SAB HR (95% CI)  HR (95% CI)a 
   PRESTO  
     
Any pain medication     
     Non-use 1,188 177  1.00 (Reference)  1.00 (Reference) 
     Any use 1,192 216 1.24 (1.01–1.52) 1.18 (0.95–1.48) 
Acetaminophen     
     Non-use 1,536 252  1.00 (Reference)  1.00 (Reference) 
     Any use    844 141 0.96 (0.77–1.21) 0.95 (0.75–1.20) 
Aspirin     
     Non-use 2,247 370  1.00 (Reference)  1.00 (Reference) 
     Any use    133   23 0.79 (0.47–1.34) 0.80 (0.47–1.36) 
Ibuprofen      
     Non-use 1,855 289   1.00 (Reference)  1.00 (Reference) 
     Any use    525 104 1.34 (1.03–1.74) 1.25 (0.95–1.64) 
Naproxen     
     Non-use 2,288 372 1.00 (Reference) 1.00 (Reference) 
     Any use      92   21 1.17 (0.57–2.41) 1.11 (0.49–2.48) 
     
HR=hazard ratio  
a Models were adjusted for age, non-Hispanic white, income, education, BMI, use of cigarettes, 
alcohol, or antibiotics during pregnancy, diagnosis of migraine headaches, diabetes, uterine 
leiomyoma, or thyroid disease. Medication specific results were also mutually adjusted for the 
other types of pain medications. 
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Table 4.6 Pain medication use before 12 gestational weeks and spontaneous abortion 
restricted to single medication users or participants with early exposure assessment  
Medication 
No. of No. of Unadjusted Adjusted 
Pregs SAB HR (95% CI)  HR (95% CI)a 
 Single medication use versus non-use 
     
Non-use 5,052 772  1.00 (Reference)  1.00 (Reference) 
Any use  2,814 516 1.25 (1.04–1.50) 1.16 (0.96–1.41) 
     Acetaminophen 2,211 383 1.15 (0.92–1.44) 1.10 (0.87–1.38) 
     Aspirin      68   12 1.20 (0.68–2.10) 1.08 (0.61–1.89) 
     Ibuprofen    572 128 1.68 (1.37–2.06) 1.44 (1.17–1.77) 
     Naproxen      31     5 1.17 (0.42–3.28) 0.99 (0.34–2.85) 
     
 Single medication use versus acetaminophen 
     
Acetaminophen 2,211 383  1.00 (Reference)  1.00 (Reference) 
Aspirin      68   12 1.04 (0.59–1.84) 0.97 (0.54–1.74) 
Ibuprofen    572 128 1.48 (1.15–1.91) 1.37 (1.06–1.78) 
Naproxen      31     5 1.07 (0.36–3.12) 0.98 (0.33–2.91) 
     
 <8 gestational weeks at exposure assessment 
     
Any pain medication     
     Non-use 2,698 425 1.00 (Reference) 1.00 (Reference) 
     Any use 2,239 486 1.42 (1.08–1.86) 1.34 (1.04–1.73) 
Acetaminophen     
     Non-use 3,116 537 1.00 (Reference) 1.00 (Reference) 
     Any use 1,821 374 1.00 (0.70–1.43) 1.03 (0.75–1.42) 
Aspirin     
     Non-use 4,622 838 1.00 (Reference) 1.00 (Reference) 
     Any use    315   73 1.01 (0.66–1.55) 1.03 (0.69–1.55) 
Ibuprofen      
     Non-use 4,003 676 1.00 (Reference) 1.00 (Reference) 
     Any use   934 235 1.56 (1.31–1.85) 1.42 (1.19–1.69) 
Naproxen     
     Non-use 4,832 884 1.00 (Reference) 1.00 (Reference) 
     Any use    105   27 1.30 (0.61–2.75) 1.10 (0.53–1.29) 
     
HR=hazard ratio 
a Models were adjusted cohort, age, non-Hispanic white, income, education, BMI, use of 
cigarettes, alcohol, or antibiotics during pregnancy, diagnosis of migraine headaches, diabetes, 
uterine leiomyoma, or thyroid disease. Medication specific results were also mutually adjusted for 
the other types of pain medications. 
 
 
 
  
95 
5 CONCLUSION 
This dissertation examined three potential risk factors for adverse 
reproductive outcomes among North American and Danish pregnancy planners.  
In the first study, we examined pregravid contraceptive use in relation to 
TTP using data pooled from three prospective cohorts of pregnancy planners, 
SG, SF, and PRESTO. We found that use of OCs, LARC methods, and the 
contraceptive ring were associated with temporary delays in return of fertility. Our 
findings indicate little effect of long-term use of these methods on fertility. These 
results were consistent with previous research examining OCs,1,2 IUDs,2,3 and 
implants.4 This was the first study to examine fecundability after use of less 
common contraceptive methods, however, there were still a small number of 
users of implants, injectables, and patches, limiting precision of these results.  
In study 2, we examined the association between pain reliever use and 
fecundability among 1,065 male pregnancy planners in PRESTO. Our study 
showed no strong deleterious effects of male preconception low-dose use of 
common pain medications on fecundability. Our results were not consistent with 
the one previous study examining acetaminophen exposure and fecundability; 
the authors observed reduced fecundability among men with the highest urinary 
concentrations of acetaminophen compared with the lowest.5 These conflicting 
results could result from differences in exposure assessment or control for 
confounding by indication (discussed in detail in Chapter 3). While pain 
medication use was common, limitations included the small number of users of 
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naproxen and aspirin, which reduced precision, and the low cumulative monthly 
dose, which limited our ability to examine dose-response relations. To our 
knowledge, this is the first study to examine fecundability after male use of 
ibuprofen, naproxen, and aspirin. 
In study 3, we examined pain medication use during early pregnancy and 
risk of SAB. Among 9,196 women who conceived without fertility treatment in 
Denmark, the United States, and Canada, we observed 1,597 SABs (17.4%). 
Low cumulative dose of ibuprofen, naproxen, or opioids was associated with 
slightly increased risk of SAB, though numbers of naproxen and opioid users 
were small. Overall, our study showed no substantial deleterious effects of 
acetaminophen or aspirin use on risk of SAB. The lack of association between 
acetaminophen6,7 or asprin33,34 use and SAB, and the association between 
NSAID6,8,9 use and SAB is consistent with prior literature. The use of a pre-
conception cohort allowed for excellent ascertainment of SAB in comparison to 
previous studies using administrative databases10 or post-conception cohorts.6,11 
The main limitation of this study was the large number of participants missing 
exposure assessment during pregnancy.   
In summary, among a non-clinical population of predominately non-
Hispanic white pregnancy planners, we found that selected pharmacologic 
agents commonly used by reproductive-aged women may increase risk of 
adverse reproductive outcomes.  
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